

ABAXIS INC
Form 10-Q
February 09, 2012

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended December 31, 2011

or

☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Commission File Number 000-19720

ABAXIS, INC.

(Exact name of registrant as specified in its charter)

California
(State of Incorporation)

77-0213001
(I.R.S. Employer Identification No.)

3240 Whipple Road
Union City, California 94587
(Address of principal executive offices)

(510) 675-6500
(Registrant's telephone number including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer ☐ Accelerated filer ☒ Non-accelerated filer ☐ Smaller reporting
o (Do not check if a smaller reporting company) company ☐

Edgar Filing: ABAXIS INC - Form 10-Q

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes ☐ No ☒

As of February 6, 2012, there were 21,690,000 shares of the registrant's common stock outstanding.

ABAXIS, INC.
Form 10-Q

For the Quarter Ended December 31, 2011

TABLE OF CONTENTS

	Page
PART I. FINANCIAL INFORMATION	
Item 1. <u>Condensed Consolidated Financial Statements (Unaudited):</u>	
<u>Condensed Consolidated Statements of Income for the Three and Nine Months Ended December 31, 2011 and 2010</u>	3
<u>Condensed Consolidated Balance Sheets as of December 31, 2011 and March 31, 2011</u>	4
<u>Condensed Consolidated Statements of Cash Flows for the Nine Months Ended December 31, 2011 and 2010</u>	5
<u>Notes to Condensed Consolidated Financial Statements</u>	6
Item 2. <u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	17
Item 3. <u>Quantitative and Qualitative Disclosures About Market Risk</u>	34
Item 4. <u>Controls and Procedures</u>	35
Item 4T. <u>Controls and Procedures</u>	35
PART II. OTHER INFORMATION	
Item 1. <u>Legal Proceedings</u>	36
Item 1A. <u>Risk Factors</u>	36
Item 2. <u>Unregistered Sales of Equity Securities and Use of Proceeds</u>	46
Item 3. <u>Defaults Upon Senior Securities</u>	46
Item 4. <u>Removed and Reserved</u>	46
Item 5. <u>Other Information</u>	46
Item 6. <u>Exhibits</u>	47
<u>SIGNATURES</u>	48

Table of Contents

PART I. FINANCIAL INFORMATION

Item 1. Condensed Consolidated Financial Statements (Unaudited)

ABAXIS, INC.
 CONDENSED CONSOLIDATED STATEMENTS OF INCOME
 (Unaudited)
 (In thousands, except share and per share data)

	Three Months Ended December 31,		Nine Months Ended December 31,	
	2011	2010	2011	2010
Revenues	\$ 37,850	\$ 35,906	\$ 113,878	\$ 106,136
Cost of revenues	17,372	16,097	52,156	46,793
Gross profit	20,478	19,809	61,722	59,343
Operating expenses:				
Research and development	2,634	2,947	9,096	9,321
Sales and marketing	9,927	8,208	28,414	25,249
General and administrative	3,280	2,820	11,194	7,596
Total operating expenses	15,841	13,975	48,704	42,166
Income from operations	4,637	5,834	13,018	17,177
Interest and other income (expense), net	(91)	46	259	698
Income before income tax provision	4,546	5,880	13,277	17,875
Income tax provision	1,696	2,045	4,892	6,711
Net income	\$ 2,850	\$ 3,835	\$ 8,385	\$ 11,164
Net income per share:				
Basic net income per share	\$ 0.13	\$ 0.17	\$ 0.38	\$ 0.50
Diluted net income per share	\$ 0.13	\$ 0.17	\$ 0.37	\$ 0.49
Shares used in the calculation of net income per share:				
Weighted average common shares outstanding - basic	21,672,000	22,398,000	22,213,000	22,309,000
Weighted average common shares outstanding - diluted	21,990,000	22,872,000	22,579,000	22,795,000

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

ABAXIS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
(In thousands, except share data)

	December 31, 2011	March 31, 2011
ASSETS		
Current assets:		
Cash and cash equivalents	\$35,368	\$43,471
Short-term investments	22,366	25,981
Receivables (net of allowances of \$254 at December 31, 2011 and \$320 at March 31, 2011)	26,041	27,880
Inventories	19,852	19,814
Prepaid expenses and other current assets	5,600	3,496
Net deferred tax assets, current	3,166	3,422
Total current assets	112,393	124,064
Long-term investments	30,189	36,237
Investment in unconsolidated affiliate	2,668	2,769
Property and equipment, net	23,448	19,637
Intangible assets, net	4,148	4,216
Net deferred tax assets, non-current	1,080	1,203
Other assets	106	134
Total assets	\$174,032	\$188,260
LIABILITIES AND SHAREHOLDERS' EQUITY		
Current liabilities:		
Accounts payable	\$6,245	\$6,173
Accrued payroll and related expenses	5,747	6,129
Accrued taxes	-	559
Other accrued liabilities	2,072	1,677
Deferred revenue	1,138	953
Warranty reserve	1,123	1,031
Total current liabilities	16,325	16,522
Non-current liabilities:		
Deferred rent	597	416
Deferred revenue	2,285	1,737
Warranty reserve	482	191
Notes payable, less current portion	808	746
Total non-current liabilities	4,172	3,090
Total liabilities	20,497	19,612
Commitments and contingencies (Note 9)		
Shareholders' equity:		
Preferred stock, no par value: 5,000,000 shares authorized; no shares issued and outstanding	-	-
Common stock, no par value: 35,000,000 shares authorized; 21,688,000 and 22,587,000 shares issued and outstanding at December 31, 2011 and at March 31, 2011, respectively	108,558	132,042
Retained earnings	44,991	36,606

Edgar Filing: ABAXIS INC - Form 10-Q

Accumulated other comprehensive loss	(14)	-
Total shareholders' equity	153,535	168,648
Total liabilities and shareholders' equity	\$174,032	\$188,260

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

ABAXIS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
(In thousands)

	Nine Months Ended December 31,	
	2011	2010
Cash flows from operating activities:		
Net income	\$8,385	\$11,164
Adjustments to reconcile net income to net cash provided by operating activities:		
Depreciation and amortization	3,725	3,326
Investment premium amortization, net	754	343
Net loss on disposals of property and equipment	10	5
Net loss (gain) on foreign exchange translation	402	(59)
Share-based compensation expense	4,194	3,547
Excess tax benefits from share-based awards	(717)	(1,908)
Provision for deferred income taxes	157	980
Equity in net loss of unconsolidated affiliate	101	-
Changes in assets and liabilities:		
Receivables, net	1,703	(1,576)
Inventories	(1,100)	(1,250)
Prepaid expenses and other current assets	(1,142)	(1,983)
Other assets	21	(36)
Accounts payable	108	(1,804)
Accrued payroll and related expenses	(380)	(452)
Accrued taxes	(559)	294
Other accrued liabilities	380	152
Deferred rent	181	212
Deferred revenue	733	205
Warranty reserve	383	(476)
Net cash provided by operating activities	17,339	10,684
Cash flows from investing activities:		
Purchases of available-for-sale investments	(8,268)	-
Purchases of held-to-maturity investments	(18,174)	(49,547)
Proceeds from maturities and redemptions of held-to-maturity investments	35,337	56,861
Purchases of property and equipment	(5,960)	(3,559)
Net cash provided by investing activities	2,935	3,755
Cash flows from financing activities:		
Proceeds from notes payable from municipal agency	147	-
Proceeds from the exercise of stock options	576	1,288
Tax withholdings related to net share settlements of restricted stock units	(2,172)	(2,004)
Repurchases of common stock	(27,328)	-
Excess tax benefits from share-based awards	717	1,908
Net cash (used in) provided by financing activities	(28,060)	1,192
Effect of exchange rate changes on cash and cash equivalents	(317)	68
Net (decrease) increase in cash and cash equivalents	(8,103)	15,699
Cash and cash equivalents at beginning of period	43,471	27,857
Cash and cash equivalents at end of period	\$35,368	\$43,556

Supplemental disclosure of cash flow information:

Cash paid for income taxes, net of refunds	\$4,809	\$5,849
--	---------	---------

Supplemental disclosure of non-cash flow information:

Change in unrealized loss on investments, net of tax	\$(14)	\$-
--	---------	-----

Transfers of equipment between inventory and property and equipment, net	\$1,130	\$746
--	---------	-------

Net change in capitalized share-based compensation	\$68	\$17
--	------	------

Common stock withheld for employee taxes in connection with share-based compensation	\$2,172	\$2,004
--	---------	---------

Repayment of notes payable by credits from municipal agency	\$70	\$-
---	------	-----

Warrants issued for intangible assets	\$388	\$-
---------------------------------------	-------	-----

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

ABAXIS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

NOTE 1. DESCRIPTION OF BUSINESS AND SIGNIFICANT ACCOUNTING POLICIES

Description of Business. Abaxis, Inc. ("Abaxis," the "Company" or "we"), incorporated in California in 1989, develops, manufactures, markets and sells portable blood analysis systems for use in the human or veterinary patient-care setting to provide clinicians with rapid blood constituent measurements. In October 2011, Abaxis began providing veterinary reference laboratory diagnostic and consulting services for veterinarians.

Abaxis Europe GmbH, our wholly-owned subsidiary in Darmstadt, Germany, markets, promotes and distributes diagnostic systems for medical and veterinary uses in the European market.

Principles of Consolidation. The accompanying unaudited condensed consolidated financial statements as of and for the three and nine month periods ended December 31, 2011 include the accounts of Abaxis and our wholly-owned subsidiary, Abaxis Europe GmbH. Intercompany transactions and balances have been eliminated in consolidation.

Basis of Presentation. We have prepared the unaudited condensed consolidated financial statements included herein pursuant to the rules and regulations of the Securities and Exchange Commission (the "SEC") for interim periods. The unaudited condensed consolidated financial statements included herein reflect all normal recurring adjustments, which are, in the opinion of our management, necessary to state fairly the results of operations and financial position for the periods presented. The results for the three and nine month periods ended December 31, 2011 are not necessarily indicative of the results to be expected for the entire fiscal year ending March 31, 2012 or for any interim or future period.

These unaudited condensed consolidated financial statements should be read in conjunction with Management's Discussion and Analysis of Financial Condition and Results of Operations and the audited financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2011.

Reclassifications. Certain reclassifications have been made to prior periods' financial statements to conform to the current period presentation. These reclassifications did not result in any change in previously reported net income, total assets or shareholders' equity.

Use of Estimates. The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires our management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Such management estimates include allowance for doubtful accounts, sales and other allowances, estimated selling price of our products, fair value of investments, valuation of inventory, fair value of intangible assets, useful lives of intangible assets, income taxes, valuation allowance for deferred tax assets, share-based compensation and warranty reserves. Our management bases their estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Our actual results may differ materially from these estimates.

Significant Accounting Policies. The significant accounting policies used in preparation of these condensed consolidated financial statements are disclosed in our Annual Report on Form 10-K for the year ended March 31, 2011 filed with the SEC on June 13, 2011, and have not changed significantly since such filing, except for the accounting standard on revenue recognition explained below.

Revenue Recognition: In October 2009, the Financial Accounting Standards Board (the “FASB”) amended the accounting standards for certain multiple deliverable revenue arrangements to:

- provide updated guidance on whether multiple deliverables exist, how the deliverables in an arrangement should be separated, and how the consideration should be allocated;
- require an entity to allocate revenue in an arrangement using estimated selling price (“ESP”) of deliverables if a vendor does not first have vendor-specific objective evidence (“VSOE”) of selling price or secondly does not have third-party evidence (“TPE”) of selling price; and
- eliminate the use of the residual method and require an entity to allocate revenue using the relative selling price method.

Our multiple-element arrangement includes the sale of one or more tangible product offerings with one or more associated services offerings, each of which are individually considered separate units of accounting. The determination of our units of accounting did not change with the adoption of the new revenue recognition guidance and as such we allocate revenue to each element in a multiple-element arrangement based upon the relative selling price of each deliverable. When applying the relative selling price method, we determine the selling price for each deliverable using VSOE of selling price, if it exists, or TPE of selling price. If neither VSOE nor TPE of selling price exist for a deliverable, we use our best estimate of selling price for that deliverable. Revenue allocated to each element is then recognized when all revenue recognition criteria are met for each element.

Table of Contents

These amendments became effective for the Company beginning on April 1, 2011 and we elected to apply the amendment prospectively to new or materially modified revenue arrangements after its effective date. The adoption of this amendment did not have a material impact on our consolidated financial position, results of operations and cash flows for the three and nine months ended December 31, 2011.

NOTE 2.

RECENT ACCOUNTING PRONOUNCEMENTS

Disclosure of Supplementary Pro Forma Information for Business Combinations: In December 2010, the FASB issued Accounting Standards Update (“ASU”) No. 2010-29, “Disclosure of Supplementary Pro Forma Information for Business Combinations,” (Topic 805) - Business Combinations (ASU 2010-29), to improve consistency in how the pro forma disclosures are calculated. The amendment enhances the disclosure requirements and requires description of the nature and amount of any material, nonrecurring pro forma adjustments directly attributable to a business combination. The amendment became effective for the Company beginning on April 1, 2011 and is applied prospectively to business combinations for which the acquisition date is after the effective date. The Company will assess the impact of the amendment if and when future business combinations occur.

Presentation of Comprehensive Income: In June 2011, the FASB issued ASU No. 2011-05, “Presentation of Comprehensive Income,” (Topic 220) - Comprehensive Income (ASU 2011-05), to require an entity to present the total of comprehensive income, the components of net income, and the components of other comprehensive income either in a single continuous statement of comprehensive income or in two separate but consecutive statements. ASU 2011-05 eliminates the currently available option to present the components of other comprehensive income as part of the statement of shareholders’ equity. The amendment does not change the items that must be reported in other comprehensive income or when an item of other comprehensive income must be reclassified to net income. The amendment will be effective for the Company beginning on April 1, 2012. As this guidance relates to presentation only, the adoption of this guidance will not have any other effect on the Company’s financial statements.

Testing Goodwill for Impairment: In September 2011, the FASB issued ASU No. 2011-08, “Testing Goodwill for Impairment,” (Topic 350) - Intangibles - Goodwill and Other (ASU 2011-08), to allow entities to use a qualitative approach to test goodwill for impairment. ASU 2011-08 permits an entity to first perform a qualitative assessment to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying value. If it is concluded that this is the case, it is necessary to perform the currently prescribed two-step goodwill impairment test. Otherwise, the two-step goodwill impairment test is not required. The amendment will be effective for the Company beginning on April 1, 2012 and earlier adoption is permitted. We are currently evaluating the impact of adopting the amendment on our consolidated financial position, results of operations or cash flows.

NOTE 3.

INVESTMENTS

Our investments are classified as either available-for-sale or held-to-maturity. The following table summarizes available-for-sale and held-to-maturity investments as of December 31, 2011 and March 31, 2011 (in thousands):

	Available-for-Sale Investments			
	Amortized Cost	Gross Unrealized Gain	Gross Unrealized (Loss)	Fair Value
December 31, 2011				
Certificates of deposits	\$1,245	\$-	\$(2)	\$1,243
Corporate bonds	6,052	5	(15)	6,042
Municipal bonds	971	-	(5)	966
Total available-for-sale investments	\$8,268	\$5	\$(22)	\$8,251

Edgar Filing: ABAXIS INC - Form 10-Q

	Held-to-Maturity Investments			
	Amortized	Gross	Gross	Fair
December 31, 2011	Cost	Unrecognized	Unrecognized	Value
		Gain	(Loss)	
Certificates of deposits	\$2,591	\$ -	\$ -	\$ 2,591
Corporate bonds	25,231	113	(356)	24,988
Municipal bonds	13,482	77	(1)	13,558
U.S. agency securities	3,000	1	-	3,001
Total held-to-maturity investments	\$44,304	\$ 191	\$ (357)	\$ 44,138

Table of Contents

		Held-to-Maturity Investments		
	Amortized	Gross Unrecognized	Gross Unrecognized	Fair
	Cost	Gain	(Loss)	Value
March 31, 2011				
Certificates of deposits	\$12,084	\$ 2	\$ -	\$12,086
Commercial paper	1,997	-	-	1,997
Corporate bonds	23,534	74	(110)	23,498
Municipal bonds	11,603	31	(5)	11,629
U.S. agency securities	13,000	7	(73)	12,934
Total held-to-maturity investments	\$62,218	\$ 114	\$ (188)	\$62,144

The amortized cost of our held-to-maturity investments approximates their fair value. As of December 31, 2011 and March 31, 2011, we did not have other-than-temporary impairment in the fair value of any individual security classified as held-to-maturity or available-for-sale. As of December 31, 2011 and March 31, 2011, we had unrealized loss on available-for-sale investments, net of related income taxes of \$14,000 and \$0, respectively. Redemptions of investments in accordance with the callable provisions during the three months ended December 31, 2011 and 2010, were \$250,000 and \$5.5 million, respectively, and during the nine months ended December 31, 2011 and 2010, were \$13.3 million and \$36.1 million, respectively.

The following table summarizes the amortized cost and fair value of our investments, classified by stated maturity as of December 31, 2011 and March 31, 2011 (in thousands):

	December 31, 2011 Available-for-Sale Investments		December 31, 2011 Held-to-Maturity Investments	
	Amortized		Amortized	
	Cost	Fair Value	Cost	Fair Value
Due in less than one year	\$ 675	\$ 674	\$ 21,692	\$ 21,648
Due in 1 to 4 years	7,593	7,577	22,612	22,490
Total investments	\$ 8,268	\$ 8,251	\$ 44,304	\$ 44,138

	March 31, 2011 Held-to-Maturity Investments	
	Amortized	
	Cost	Fair Value
Due in less than one year	\$ 25,981	\$ 25,988
Due in 1 to 4 years	36,237	36,156
Total investments	\$ 62,218	\$ 62,144

NOTE 4.

FAIR VALUE MEASUREMENTS

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability ("exit price") in an orderly transaction between market participants at the measurement date. FASB Accounting Standards Codification ("ASC") 820, "Fair Value Measurements and Disclosures," establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity's own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities

(Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:

Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities.

Level 2: Directly or indirectly observable inputs as of the reporting date through correlation with market data, including quoted prices for similar assets and liabilities in active markets and quoted prices in markets that are not active. Level 2 also includes assets and liabilities that are valued using models or other pricing methodologies that do not require significant judgment since the input assumptions used in the models, such as interest rates and volatility factors, are corroborated by readily observable data from actively quoted markets for substantially the full term of the financial instrument.

Level 3: Unobservable inputs that are supported by little or no market data and require the use of significant management judgment. These values are generally determined using pricing models for which the assumptions utilize management's estimates of market participant assumptions.

Table of Contents

The following table summarizes financial assets, measured at fair value on a recurring basis, by level within the fair value hierarchy as of December 31, 2011 and March 31, 2011 (in thousands):

As of December 31, 2011				
	Quoted Prices in Active Markets for Identical Assets Level 1	Significant Other Observable Inputs Level 2	Significant Unobservable Inputs Level 3	Total
Assets				
Cash equivalents	\$ 1,202	\$ -	\$ -	\$ 1,202
Available-for-sale investments:				
Certificates of deposits	-	1,243	-	1,243
Corporate bonds	-	6,042	-	6,042
Municipal bonds	-	966	-	966
Total assets at fair value	\$ 1,202	\$ 8,251	\$ -	\$ 9,453

As of March 31, 2011				
	Quoted Prices in Active Markets for Identical Assets Level 1	Significant Other Observable Inputs Level 2	Significant Unobservable Inputs Level 3	Total
Assets				
Cash equivalents	\$ 2,415	\$ -	\$ -	\$ 2,415
Total assets at fair value	\$ 2,415	\$ -	\$ -	\$ 2,415

As of December 31, 2011 and March 31, 2011, our Level 1 financial assets are comprised of money market mutual funds. Our cash equivalents are highly liquid instruments with original or remaining maturities of three months or less at the time of purchase that are readily convertible into cash. The fair value of our Level 1 financial assets is based on quoted market prices of the underlying security.

As of December 31, 2011, our Level 2 financial assets are comprised of certificates of deposits, corporate bonds and municipals bonds. We review trading activity and pricing for these investments as of the measurement date. When sufficient quoted pricing for identical securities is not available, we use market pricing and other observable market inputs for similar securities obtained from third party data providers. These inputs represent quoted prices for similar assets in active markets or these inputs have been derived from observable market data. This approach results in the classification of these securities as Level 2 of the fair value hierarchy.

As of December 31, 2011 and March 31, 2011, we did not have any Level 3 financial assets or liabilities measured at fair value on a recurring basis. During the three and nine months ended December 31, 2011 and 2010, we did not have any Level 3 financial assets or liabilities on a recurring basis.

NOTE 5.

INVENTORIES

Inventories include material, labor and overhead, and are stated at the lower of cost (first-in, first-out method) or market. Components of inventories were as follows (in thousands):

	December 31, 2011	March 31, 2011
Raw materials	\$ 9,081	\$9,950
Work-in-process	2,626	2,323
Finished goods	8,145	7,541
Inventories	\$ 19,852	\$19,814

NOTE 6.

INVESTMENT IN UNCONSOLIDATED AFFILIATE

Our investment in an unconsolidated affiliate consists of an investment in equity securities of Scandinavian Micro Biodevices APS (“SMB”). In February 2011, we purchased a 15% equity ownership interest in SMB, for \$2.8 million in cash. SMB is a privately-held developer and manufacturer of point-of-care diagnostic products for veterinary use. SMB, based in Farum, Denmark, has been the original equipment manufacturer of the Abaxis VetScan VSpro point-of-care coagulation and specialty analyzer since 2008. Abaxis has had exclusive distribution rights for the analyzer and associated cartridges in North America since 2008. Starting January 2011, Abaxis has non-exclusive rights in other areas of the world. We accounted for our investment in SMB using the equity method due to our significant influence over SMB’s operations. During the three and nine months ended December 31, 2011, we recorded our allocated portion of SMB’s net loss of \$29,000 and \$101,000, respectively.

Table of Contents

NOTE 7.

WARRANTY RESERVES

We provide for the estimated future costs to be incurred under our standard warranty obligation on our instruments and reagent discs.

Instruments. Our standard warranty obligation on instruments ranges from one to three years. The estimated contractual warranty obligation is recorded when the related revenue is recognized and any additional amount is recorded when such cost is probable and can be reasonably estimated. Cost of revenues reflects estimated warranty expense for instruments sold in the current period and any adjustments in estimated warranty expense for the installed base under our standard warranty obligation based on our quarterly evaluation of service experience. The estimated accrual for warranty exposure is based on historical experience as to product failures, estimated product failure rates, estimated repair costs, material usage and freight incurred in repairing the instrument after failure and known design changes under the warranty plan.

During the nine months ended December 31, 2011, we recorded an additional accrual to pre-existing warranties of \$257,000, which increased our warranty reserves and our cost of revenues, based on both historical and projected product performance rates. Management continually evaluates the sufficiency of the warranty provisions and makes adjustments when necessary. If an unusual performance rate related to warranty claims is noted, an additional warranty accrual may be assessed and recorded when a failure event is probable and the cost can be reasonably estimated.

Reagent Discs. We record a provision for defective reagent discs when the related sale is recognized and any additional amount is recorded when such cost is probable and can be reasonably estimated. The warranty cost includes the replacement costs and freight of a defective reagent disc. During the three and nine months ended December 31, 2011, the provision for warranty expense related to replacement of defective reagent discs was \$105,000 and \$299,000, respectively. The balance of accrued warranty reserve related to replacement of defective reagent discs at December 31, 2011 and 2010 was \$460,000 and \$401,000, respectively, which was classified as a current liability on the condensed consolidated balance sheets.

We evaluate our estimates for warranty reserves on an ongoing basis and believe we have the ability to reasonably estimate warranty costs. However, unforeseeable changes in factors may impact the estimate for warranty and such changes could cause a material change in our warranty reserve accrual in the period in which the change was identified.

The change in our accrued warranty reserve during the three and nine months ended December 31, 2011 and 2010 is summarized as follows (in thousands):

	Three Months Ended December 31,		Nine Months Ended December 31,	
	2011	2010	2011	2010
Balance at beginning of period	\$1,436	\$851	\$1,222	\$1,343
Provision for warranty expense	500	319	1,113	729
Warranty costs incurred	(331)	(153)	(987)	(491)
Adjustment to pre-existing warranties	-	(150)	257	(714)
Balance at end of period	1,605	867	1,605	867
Non-current portion of warranty reserve	482	95	482	95
Current portion of warranty reserve	\$1,123	\$772	\$1,123	\$772

NOTE 8.

BORROWINGS

Notes Payable. Effective January 2011, we have a ten year loan agreement with the Community Redevelopment Agency of the City of Union City (“the Agency”) whereby the Agency provides us with an unsecured loan of up to \$1.0 million, primarily to purchase capital equipment. The loan bears interest at 5.0% and is payable quarterly. As of December 31, 2011, our short-term and long-term notes payable balances were \$100,000 and \$808,000, respectively, and we recorded the short-term balance in other accrued liabilities on the condensed consolidated balance sheets. The entire outstanding balance of the note shall be payable in full on the earlier of: (i) December 2020, or (ii) the date Abaxis ceases operations in Union City, California. The Agency also has the right to accelerate the maturity date and declare all balances immediately due and payable upon the event of default as defined in the loan agreement. We evaluate covenants in our loan agreement on a quarterly basis, and we were in compliance with such covenants as of December 31, 2011.

In accordance with the terms of the loan agreement, the Agency will provide Abaxis with an annual credit that can be applied against the accrued interest and outstanding principal balance on a quarterly basis. The Agency determines the annual credit based on certain taxes paid by Abaxis to the City of Union City, California for a specified period, as defined in the loan agreement. We anticipate that our annual credits from the Agency will be used to fully repay our notes payable due to the Agency. We may carry forward unused quarterly credits to apply against our outstanding balance in a future period. Credits applied to repay our notes payable and accrued interest are recorded in “Interest and other income (expense), net” on the condensed consolidated statements of income.

Table of Contents

NOTE 9.

COMMITMENTS AND CONTINGENCIES

Purchase Commitments. In October 2008, we entered into an original equipment manufacturing (“OEM”) agreement with SMB of Denmark to purchase coagulation and specialty analyzers and related cartridges. Effective January 2011, we amended and restated our OEM agreement, including the terms of our minimum purchase commitments. Under the amended agreement, we committed to purchase a minimum number of coagulation and specialty analyzers and related cartridges on an annual basis during each calendar year 2011 through 2015. Our purchase obligations in the future may be adjusted if our minimum purchase commitments are not met during a calendar year period. At December 31, 2011, our total remaining outstanding commitment due is approximately \$11.5 million.

In December 2011, we executed a term sheet to enter into a development and supply equipment agreement with Diatron MI PLC (“Diatron”) of Hungary to purchase Diatron hematology instruments. Under the terms of this agreement, we committed to purchase a minimum number of hematology instruments on an annual basis during each calendar year 2012 through 2014, which can be amended upon agreement by both parties. At December 31, 2011, our outstanding commitment due is approximately \$12.6 million. The commitment amount is based on the minimum number of hematology instruments that we are required to purchase, the cost of the instruments and the Euro exchange rate at period-end. Since the exchange rate can fluctuate in the future, the commitment in absolute dollars will change accordingly.

Patent Licensing Agreement. Effective January 2009, we entered into a license agreement with Inverness Medical Switzerland GmbH, now known as Alere Switzerland GmbH (“Alere”). Under our license agreement, we licensed co-exclusively certain worldwide patent rights related to lateral flow immunoassay technology in the field of animal health diagnostics in the professional marketplace. The license agreement provides that Alere shall not grant any future rights to any third parties under its current lateral flow patent rights in the animal health diagnostics field in the professional marketplace. The license agreement enables us to develop and market products under rights from Alere to address animal health and laboratory animal research markets.

In exchange for the license rights, we (i) paid an up-front license fee of \$5.0 million to Alere in January 2009, (ii) agreed to pay royalties during the term of the agreement, based solely on sales of products in a jurisdiction country covered by valid and unexpired claims in that jurisdiction under the licensed Alere patent rights, and (iii) agreed to pay a yearly minimum license fee of between \$500,000 to \$1.0 million per year, which fee will be creditable against any royalties due during such calendar year. The royalties, if any, are payable through the date of the expiration of the last valid patent licensed under the agreement that includes at least one claim in a jurisdiction covering products we sell in that jurisdiction. The yearly minimum fees became payable starting in fiscal 2011 for so long as we desire to maintain exclusivity under the agreement.

Litigation. On June 28, 2010, we filed a patent infringement lawsuit against Cepheid with respect to Cepheid’s Methicillin-resistant Staphylococcus aureus (MRSA) product, on which Cepheid has ceased paying license royalties. On December 17, 2010, Cepheid filed its amended answer and certain counterclaims seeking findings of no breach of contract, non-infringement, unenforceability and invalidity of the asserted patents, and a declaration regarding the patent term of one of the patents. We believe the counterclaims raised by Cepheid are without merit and intend to contest them vigorously. Because of the cost involved in pursuing patent infringement cases, we believe the cost of this litigation could have a material adverse effect on Abaxis, our consolidated financial position and results of operations. As of December 31, 2011, we had not recorded future litigation and related expenses to pursuing the patent infringement case and an estimate of such costs cannot be made at this time. A claims construction hearing was held in June 2011 and the court has issued its claims construction order. The case is ongoing. A trial date has been set for September 24, 2012.

We are involved from time to time in various litigation matters in the normal course of business. Other than as described above, we believe that the ultimate resolution of these matters will not have a material effect on our consolidated financial position or results of operations. There can be no assurance that existing or future legal proceedings arising in the ordinary course of business or otherwise will not have a material adverse effect on our business, consolidated financial position, results of operations or cash flows.

NOTE 10.

SHARE REPURCHASES

Share repurchase activity is as follows (in thousands, except share and average per share cost data):

	Three Months Ended December 31, 2011	Nine Months Ended December 31, 2011
Number of shares repurchased	-	1,168,000
Total cost	\$ -	\$ 27,328
Average per share cost including commissions	\$ -	\$ 23.41

In August 2011, the Board of Directors authorized the repurchase of up to an aggregate of \$40.0 million of our common stock. As of December 31, 2011, \$12.7 million of share repurchases may yet be purchased under such authorization. In January 2012, the Board of Directors approved a \$15.0 million increase to its existing share repurchase program, to a total of \$55.0 million. The repurchases are made from time to time on the open market at prevailing market prices or in negotiated transactions off the market. Repurchased shares are retired.

Table of Contents

NOTE 11.

SHARE-BASED COMPENSATION

In accordance with ASC 718, "Compensation-Stock Compensation," we recognize share-based compensation expense, net of an estimated forfeiture rate, over the requisite service period of the award to employees and directors. The following table summarizes total share-based compensation expense, net of tax, related to restricted stock units during the three and nine months ended December 31, 2011 and 2010, which is included in our condensed consolidated statements of income (in thousands, except per share data):

	Three Months Ended December 31,		Nine Months Ended December 31,	
	2011	2010	2011	2010
Cost of revenues	\$187	\$168	\$698	\$475
Research and development	226	195	641	684
Sales and marketing	475	365	1,402	1,139
General and administrative	624	570	1,453	1,249
Share-based compensation expense before income taxes	1,512	1,298	4,194	3,547
Income tax benefit	(526)	(476)	(1,459)	(1,327)
Total share-based compensation expense after income taxes	\$986	\$822	\$2,735	\$2,220
Net impact of share-based compensation on:				
Basic net income per share	\$0.05	\$0.04	\$0.12	\$0.10
Diluted net income per share	\$0.04	\$0.04	\$0.12	\$0.10

Share-based compensation has been classified in the condensed consolidated statements of income or capitalized on the condensed consolidated balance sheets in the same manner as cash compensation paid to employees. Capitalized share-based compensation costs at December 31, 2011 and March 31, 2011 were \$175,000 and \$107,000, respectively, which were included in inventories on our condensed consolidated balance sheets.

Cash Flow Impact

The accounting standard with respect to share-based payment requires cash flows resulting from excess tax benefits to be classified as a part of cash flows from financing activities. Excess tax benefits are realized tax benefits from tax deductions for exercised stock options and vested restricted stock units in excess of the deferred tax asset attributable to share-based compensation expense for such share-based awards. Excess tax benefits are considered realized when the tax deductions reduce taxes that otherwise would be payable. Excess tax benefits classified as a financing cash inflow for the three months ended December 31, 2011 and 2010 were \$231,000 and \$1.4 million, respectively, and for the nine months ended December 31, 2011 and 2010 were \$717,000 and \$1.9 million, respectively.

Equity Compensation Plans

Our share-based compensation plans are described below.

2005 Equity Incentive Plan. Our 2005 Equity Incentive Plan (the "Equity Incentive Plan") restated and amended our 1998 Stock Option Plan. The Equity Incentive Plan allows for the awards of stock options, stock appreciation rights, restricted stock awards, restricted stock units, performance cash awards, performance shares, performance units, deferred compensation awards or other share-based awards to employees, directors and consultants. On October 27, 2010, our shareholders approved an amendment to the Equity Incentive Plan to (i) increase the aggregate number of shares of common stock reserved for issuance under the Equity Incentive Plan by 500,000 shares, (ii) clarify that we may continue to grant performance cash awards under the Equity Incentive Plan and (iii) reapprove the Internal Revenue Code Section 162(m) performance criteria and award limits of the Equity Incentive Plan to permit us to

continue to grant awards to key officers that qualify as performance-based compensation under Section 162(m) of the Internal Revenue Code. As of December 31, 2011, the Equity Incentive Plan provides for the issuance of a maximum of 5,886,000 shares, of which 296,000 shares of common stock were then available for future issuance. Shares that are canceled or forfeited from an award and shares withheld in satisfaction of tax withholding obligations are again available for issue under the Equity Incentive Plan.

Options granted to employees and directors generally expire ten years from the grant date. Options granted to employees generally become exercisable over a period of four years based on cliff-vesting terms and continuous employment. Options granted to non-employee directors generally become exercisable over a period of one year based on monthly vesting terms and continuous service. See the “Stock Options” section in this Note for additional information.

Restricted stock units awarded to employees generally vest over a period of four years and the awards may also be subject to accelerated vesting upon achieving certain performance-based milestones and continuous employment during the vesting period. Restricted stock units awarded to non-employee directors generally vest in full one year after the grant date based on continuous service. See the “Restricted Stock Units” section in this Note for additional information.

1992 Outside Directors’ Stock Option Plan. Under our 1992 Outside Directors’ Stock Option Plan (the “Directors Plan”), options to purchase shares of common stock were automatically granted, annually, to non-employee directors. Options under the Directors Plan were nonqualified stock options and were granted at the fair market value on the date of grant and expired ten years from the date of grant. Options granted to non-employee directors generally become exercisable over a period of one year based on monthly vesting terms and continuous service. The Directors Plan provided for the issuance of a maximum of 250,000 shares. As of December 31, 2011, there were no stock options outstanding under the Directors Plan. Additionally, no shares of common stock were available for future issuance because the time period for granting options expired in June 2002 in accordance with the terms of the Directors Plan.

Table of Contents

Our current practice is to issue new shares of common stock from our authorized shares for share-based awards upon the exercise of stock options or vesting of restricted stock units.

Stock Options

Prior to April 1, 2006, we granted stock options to employees, with an exercise price equal to the closing market price of our common stock on the date of grant and with cliff-vesting terms over four years, conditional on continuous employment with the Company. In addition, prior to April 1, 2006, we granted stock options to non-employee directors with an exercise price equal to the closing market price of our common stock on the date of grant and became exercisable over a period of one year based on monthly vesting terms, conditional on continuous service to the Company. There were no stock options granted since the beginning of fiscal 2007 and we did not grant stock options during the nine months ended December 31, 2011. We have recognized compensation expense during the requisite service period of the stock option. As of December 31, 2011, we had no unrecognized compensation expense related to stock options granted.

Stock Option Activity

The following table summarizes information regarding options outstanding and options exercisable at December 31, 2011 and the changes during the nine-month period then ended:

	Number of Shares	Average Exercise Price Per Share	Average Remaining Contractual Life (Years)	Aggregate Intrinsic Value (In thousands)
Outstanding at March 31, 2011	406,000	\$ 12.10		
Granted	-	-		
Exercised	(113,000)	5.12		
Canceled or forfeited	(2,000)	5.31		
Outstanding at December 31, 2011	291,000	\$ 14.84	2.00	\$ 3,738
Vested and expected to vest at December 31, 2011	291,000	\$ 14.84	2.00	\$ 3,738
Exercisable at December 31, 2011	291,000	\$ 14.84	2.00	\$ 3,738

The aggregate intrinsic value in the table above represents the pre-tax intrinsic value, based on our closing stock price as of December 30, 2011, (the last trading day for the quarterly period ended December 31, 2011), that would have been received by the option holders had all option holders exercised their stock options as of that date. Total intrinsic value of stock options exercised during the three months ended December 31, 2011 and 2010 was \$370,000 and \$3.9 million, respectively, and during the nine months ended December 31, 2011 and 2010 was \$2.3 million and \$5.0 million, respectively. Cash proceeds from stock options exercised during the three months ended December 31, 2011 and 2010 were \$146,000 and \$839,000, respectively, and during the nine months ended December 31, 2011 and 2010 were \$576,000 and \$1.3 million, respectively.

Restricted Stock Units

We grant restricted stock unit awards to employees and directors as part of our share-based compensation program which began in fiscal 2007. The restricted stock unit awards entitle holders to receive shares of common stock at the end of a specified period of time. Vesting for restricted stock unit awards is based on continuous employment or service of the holder. Upon vesting, the equivalent number of common shares are typically issued net of tax withholdings. If the vesting conditions are not met, unvested restricted stock unit awards will be forfeited. Generally, the restricted stock unit awards vest according to one of the following time-based vesting schedules:

- Restricted stock unit awards to employees: Four-year time-based vesting as follows: five percent vesting after the first year; additional ten percent after the second year; additional 15 percent after the third year; and the remaining 70 percent after the fourth year of continuous employment with the Company.
- Restricted stock unit awards to non-employee directors: 100 percent vesting after one year of continuous service to the Company.

From time to time, restricted stock unit awards granted to employees may be subject to accelerated vesting upon achieving certain performance-based milestones. Additionally, the Compensation Committee of our Board of Directors (the “Compensation Committee”), in its discretion, may provide in the event of a change in control for the acceleration of vesting and/or settlement of the restricted stock unit held by a participant upon such conditions and to such extent as determined by the Compensation Committee. Our Board of Directors has adopted an executive change in control severance plan, which it may terminate or amend at any time, that provides that awards granted to executive officers will accelerate fully on a change of control. The vesting of non-employee director awards granted under the Equity Incentive Plan automatically will also accelerate in full upon a change in control.

Table of Contents

The fair value of restricted stock unit awards used in our expense recognition method is measured based on the number of shares granted and the closing market price of our common stock on the date of grant. Such value is recognized as an expense over the corresponding requisite service period. The share-based compensation expense is reduced for an estimate of the restricted stock unit awards that are expected to be forfeited. The forfeiture estimate is based on historical data and other factors, and compensation expense is adjusted for actual results. As of December 31, 2011, the total unrecognized compensation expense related to restricted stock unit awards granted amounted to \$20.8 million, which is expected to be recognized over a weighted average service period of 2.29 years.

Restricted Stock Unit Activity

The following table summarizes restricted stock unit activity for the nine months ended December 31, 2011:

	Number of Shares	Weighted Average Grant Date Fair Value(1)
Unvested at March 31, 2011	940,000	\$ 22.09
Granted	436,000	27.25
Vested(2)	(234,000)	22.04
Canceled or forfeited	(16,000)	23.32
Unvested at December 31, 2011	1,126,000	\$ 24.08

(1) The weighted average grant date fair value of restricted stock units is based on the number of shares and the closing market price of our common stock on the date of grant.

(2) The number of restricted stock units vested includes shares that we withheld on behalf of our employees to satisfy the statutory tax withholding requirements.

Total intrinsic value of restricted stock units vested during the three months ended December 31, 2011 and 2010 was \$608,000 and \$118,000, respectively, and during the nine months ended December 31, 2011 and 2010 was \$6.5 million and \$5.9 million, respectively. The total grant date fair value of restricted stock units vested during the three months ended December 31, 2011 and 2010 was \$598,000 and \$129,000, respectively, and during the nine months ended December 31, 2011 and 2010 was \$5.1 million and \$5.7 million, respectively.

NOTE 12.

COMMON STOCK WARRANTS

At December 31, 2011, there were 30,000 warrants outstanding, of which 6,000 shares vested, to purchase common stock at a weighted average exercise price of \$3.00 per share, expiring in fiscal years 2016 through 2017. At March 31, 2011, there were 10,000 warrants outstanding, of which 2,000 shares vested, to purchase common stock at a weighted average exercise price of \$3.00 per share, expiring in January 2016. The fair value of the warrants issued were determined using the Black-Scholes option-pricing model and are amortized over their estimated useful life, of approximately ten years, as an intangible asset.

In January 2011, we issued warrants to purchase 10,000 shares of Abaxis common stock to National Institute for Strategic Technology Acquisition and Commercialization ("NISTAC") in connection with our Master Agreement with two entities affiliated with Kansas State University, NISTAC, and the Kansas State University Research Foundation ("KSURF"). The exercise price of the warrants issued were \$3.00 per share and vests at a rate of 20% annually from its issuance date and has a term of five years. In October 2011, we issued additional warrants to NISTAC to purchase 20,000 shares of our common stock, pursuant to the Master Agreement. These warrants were issued based on the date

that Abaxis first receives samples from a paying customer, as described in our Master Technical Testing Services Agreement with the Kansas State University and K-State Diagnostic and Analytical Services Inc. The exercise price of these warrants issued were \$3.00 per share and vests at a rate of 20% annually from its issuance date and has a term of five years.

NOTE 13.NET INCOME PER SHARE

Basic net income per share is computed by dividing the net income attributable to common shareholders by the weighted average number of common shares outstanding during the period. Diluted net income per share is computed by dividing the net income attributable to common shareholders by the weighted average number of common shares that would have been outstanding during the period assuming the issuance of common shares for all potential dilutive common shares outstanding using the treasury stock method. Dilutive potential common shares outstanding include outstanding stock options, restricted stock units and warrants.

Table of Contents

The following is a reconciliation of the weighted average number of common shares outstanding used in calculating basic and diluted net income per share (in thousands, except share and per share data):

	Three Months Ended December 31,		Nine Months Ended December 31,	
	2011	2010	2011	2010
Numerator:				
Net income	\$ 2,850	\$ 3,835	\$ 8,385	\$ 11,164
Denominator:				
Weighted average common shares outstanding - basic	21,672,000	22,398,000	22,213,000	22,309,000
Weighted average effect of dilutive securities:				
Stock options	107,000	297,000	139,000	312,000
Restricted stock units	185,000	177,000	212,000	174,000
Warrants	26,000	-	15,000	-
Weighted average common shares outstanding - diluted	21,990,000	22,872,000	22,579,000	22,795,000
Net income per share:				
Basic net income per share	\$ 0.13	\$ 0.17	\$ 0.38	\$ 0.50
Diluted net income per share	\$ 0.13	\$ 0.17	\$ 0.37	\$ 0.49

Stock options are excluded from the computation of diluted weighted average shares outstanding if the exercise price of the stock options is greater than the average market price of our common stock during the period because the inclusion of these stock options would be antidilutive to net income per share. During the three and nine months ended December 31, 2011 and 2010, there were no stock options excluded from the computation of diluted weighted average shares outstanding.

We excluded the following restricted stock units from the computation of diluted weighted average shares outstanding because the inclusion of these awards would be antidilutive to net income per share:

	Three Months Ended December 31,		Nine Months Ended December 31,	
	2011	2010	2011	2010
Weighted average number of shares underlying antidilutive restricted stock units	307,000	58,000	249,000	269,000

NOTE 14.

INCOME TAXES

During the three months ended December 31, 2011 and 2010, our income tax provision was \$1.7 million, based on an effective tax rate of 37%, and \$2.0 million, based on an effective tax rate of 35%, respectively. The increase in the effective tax rate during the three months ended December 31, 2011, as compared to the three months ended December 31, 2010, was primarily due to tax benefits resulting from the retroactive extension of the federal research and development tax credit during the three months ended December 31, 2010, partially offset by an expense recognized during the three months ended December 31, 2010 as a result of a decrease in California deferred tax assets due to a change in tax law impacting California apportionment.

During the nine months ended December 31, 2011 and 2010, our income tax provision was \$4.9 million, based on an effective tax rate of 37%, and \$6.7 million, based on an effective tax rate of 38%, respectively. The decrease in the

effective tax rate during the nine months ended December 31, 2011, as compared to the nine months ended December 31, 2010, was primarily due to lower state tax expenses resulting from the change in California to a single factor apportionment.

We did not have any unrecognized tax benefits as of December 31, 2011 or December 31, 2010. During the three and nine months ended December 31, 2011 and 2010, we did not recognize any interest or penalties related to unrecognized tax benefits.

NOTE COMPREHENSIVE INCOME

15.

The following is a summary of comprehensive income for the three and nine months ended December 31, 2011 and 2010 (in thousands):

	Three Months Ended December 31,		Nine Months Ended December 31,	
	2011	2010	2011	2010
Net income	\$2,850	\$3,835	\$8,385	\$11,164
Other comprehensive loss:				
Net change in unrealized loss on investments, net of tax	(14)	-	(14)	-
Comprehensive income	\$2,836	\$3,835	\$8,371	\$11,164

Table of Contents

NOTE 16.

SEGMENT REPORTING INFORMATION

Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by our chief operating decision maker, or decision making group, in deciding how to allocate resources and in assessing performance.

Abaxis develops, manufactures, markets and sells portable blood analysis systems for use in the human or veterinary patient-care setting to provide clinicians with rapid blood constituent measurements. We identify our reportable segments as those customer groups that represent more than 10% of our combined revenue or gross profit or loss of all reported operating segments. We manage our business on the basis of the following two reportable segments: (i) the medical market and (ii) the veterinary market, which are based on the products sold and services performed by market and customer group. For the products that we manufacture and sell, each reportable segment has similar manufacturing processes, technology and shared infrastructures. The accounting policies for segment reporting are the same as for the Company as a whole. We do not segregate assets by segments since our chief operating decision maker, or decision making group, does not use assets as a basis to evaluate a segment's performance.

Medical Market

In the medical market reportable segment, we serve a worldwide customer group consisting of military installations (ships, field hospitals and mobile care units), physicians' office practices across all specialties, urgent care, outpatient and walk-in clinics (free-standing or hospital-connected), health screening operations, home care providers (national, regional or local), nursing homes, ambulance companies, oncology treatment clinics, dialysis centers, pharmacies and hospital labs. The products manufactured and sold in this segment primarily consist of Piccolo chemistry analyzers and medical reagent discs.

Veterinary Market

In the veterinary market reportable segment, we serve a worldwide customer group consisting of companion animal hospitals, animal clinics with mixed practices of small animals, birds and reptiles, equine and bovine practitioners, veterinary emergency clinics, veterinary referral hospitals, universities, government, pharmaceutical companies, biotechnology companies and private research laboratories. The products manufactured and sold in this segment primarily consist of VetScan chemistry analyzers and veterinary reagent discs. We also sell OEM supplied products in this segment consisting of VetScan hematology instruments and related reagent kits, VetScan VSpro coagulation and specialty analyzers and related consumables, VetScan i-STAT analyzers and related VetScan i-STAT consumables and rapid tests. During fiscal 2011, we began developing Abaxis Veterinary Reference Laboratories ("AVRL"), a full-service laboratory testing facility, based in Olathe, Kansas. In October 2011, we began operating and providing veterinary reference laboratory diagnostic and consulting services for veterinarians in the United States through AVRL.

The table below summarizes revenues, cost of revenues and gross profit from our two operating segments and from certain unallocated items for the three and nine months ended December 31, 2011 and 2010 (in thousands):

	Three Months Ended December 31, 2011		Nine Months Ended December 31, 2011	
	2011	2010	2011	2010
Revenues:				
Medical Market	\$8,147	\$8,126	\$22,636	\$21,421
Veterinary Market	28,467	26,283	87,684	79,750
Other(1)	1,236	1,497	3,558	4,965

Edgar Filing: ABAXIS INC - Form 10-Q

Total revenues	37,850	35,906	113,878	106,136
Cost of revenues:				
Medical Market	3,514	3,721	10,180	9,927
Veterinary Market	12,472	11,153	37,893	33,209
Other(1)	1,386	1,223	4,083	3,657
Total cost of revenues	17,372	16,097	52,156	46,793
Gross profit:				
Medical Market	4,633	4,405	12,456	11,494
Veterinary Market	15,995	15,130	49,791	46,541
Other(1)	(150)	274	(525)	1,308
Gross profit	\$20,478	\$19,809	\$61,722	\$59,343

(1) Represents unallocated items, not specifically identified to any particular business segment.

Table of ContentsNOTE REVENUES BY PRODUCT AND SERVICE CATEGORY AND GEOGRAPHIC REGION AND
17. SIGNIFICANT CONCENTRATIONS

Revenue Information

The following is a summary of our revenues by product and service category (in thousands):

Revenues by Product and Service Category	Three Months Ended December 31,		Nine Months Ended December 31,	
	2011	2010	2011	2010
Instruments(1)	\$9,079	\$9,289	\$25,364	\$24,256
Consumables(2)	26,808	24,509	83,019	75,136
Other products and services(3)	1,925	1,753	5,372	5,558
Product and service revenues, net	37,812	35,551	113,755	104,950
Development and licensing revenue	38	355	123	1,186
Total revenues	\$37,850	\$35,906	\$113,878	\$106,136

(1) Instruments include chemistry analyzers, hematology instruments, VSpro coagulation and specialty analyzers and i-STAT analyzers.

(2) Consumables include reagent discs, hematology reagent kits, VSpro coagulation and specialty cartridges, i-STAT cartridges and rapid tests.

(3) Other products and services include veterinary reference laboratory diagnostic and consulting services.

The following is a summary of revenues by geographic region based on customer location (in thousands):

Revenues by Geographic Region	Three Months Ended December 31,		Nine Months Ended December 31,	
	2011	2010	2011	2010
North America	\$31,847	\$30,068	\$93,540	\$87,385
Europe	4,516	4,508	16,326	14,838
Asia Pacific and rest of the world	1,487	1,330	4,012	3,913
Total revenues	\$37,850	\$35,906	\$113,878	\$106,136

Significant Concentrations

During the three months ended December 31, 2011, one distributor in the United States, Animal Health International, accounted for 15% of our total worldwide revenues. During the nine months ended December 31, 2011, one distributor in the United States, Animal Health International, accounted for 12% of our total worldwide revenues. Animal Health International was formed in 2011 from two animal health companies, which included Walco International, Inc., d/b/a DVM Resources. During the three and nine months ended December 31, 2010, there were no distributors or direct customers that accounted for 10% or more of our total worldwide revenues.

At December 31, 2011, one distributor in the United States accounted for 19% of our total receivables balance. At December 31, 2010, one distributor in the United States accounted for 14% of our total receivables balance.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

FORWARD-LOOKING STATEMENTS

This Management's Discussion and Analysis of Financial Condition and Results of Operations includes a number of forward-looking statements, which reflect our current views with respect to future events and financial performance. In this report, the words "will," "anticipates," "believes," "expects," "intends," "plans," "future," "projects," "estimates," "would," "may," "could," "should," "might," and similar expressions identify forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties, including but not limited to those discussed below, in Part II, Item 1A of this report and in Part I, Item 1A of our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC"), that could cause actual results to differ materially from historical results or those anticipated. Such risks and uncertainties include, but are not limited to, the vulnerability of our manufacturing operations to potential interruptions and delays, fluctuations in our quarterly results of operations and difficulty in predicting future results, our dependence on certain sole or limited source suppliers, market acceptance of our products and services, the continuing development of our products, protection of Abaxis' intellectual property or claims of infringement of intellectual property asserted by third parties, risks involved in carrying of inventory, development of our sales, marketing and distribution experience, our ability to attract, train and retain competent sales personnel, general market conditions, competition and other risks detailed under "Risk Factors" in this Quarterly Report on Form 10-Q. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We assume no obligation to update any forward-looking statements as circumstances change.

Table of Contents

BUSINESS OVERVIEW

Company Description

Abaxis, Inc. develops, manufactures, markets and sells portable blood analysis systems for use in the human or veterinary patient-care setting to provide clinicians with rapid blood constituent measurements. In October 2011, Abaxis also began providing veterinary reference laboratory diagnostic and consulting services for veterinarians.

Abaxis, Inc. (“Abaxis,” “the Company,” “us” or “we”) was incorporated in California in 1989. Our principal offices are located at 3240 Whipple Road, Union City, California 94587. Our telephone number is (510) 675-6500 and our Internet address is www.abaxis.com. We make available free of charge on or through our Internet website our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and all amendments to those reports as soon as reasonably practicable after such material is electronically filed with or furnished to the SEC. Our common stock trades on the NASDAQ Global Market under the symbol “ABAX.”

Our corporate headquarters are located in Union City, California, from which we conduct our manufacturing, warehousing, research and development, regulatory, sales and marketing and administrative activities. We market and sell our products worldwide by maintaining direct sales forces and through independent distributors. Our sales force is primarily located in the United States. Abaxis Europe GmbH, our wholly-owned subsidiary in Germany since July 2008, markets and distributes diagnostic systems for medical and veterinary uses in the European market.

Products and Services. We manage our business in two operating segments, based on the products sold and services provided by market and customer group in the medical market and veterinary market.

Point-of-Care Blood Chemistry Analyzers. Our primary product is a blood analysis system, consisting of a compact portable analyzer and a series of single-use plastic discs, called reagent discs, containing all the chemicals required to perform a panel of up to 14 tests on human patients and 13 tests on veterinary patients. We market our blood chemistry analyzers in both the medical market and the veterinary market, as described below.

- **Medical Market:** We currently market the blood analysis system in the medical market under the name Piccolo® Xpress. Through October 2006, we marketed the blood analysis system in the medical market as the Piccolo, now referred to as the Piccolo Classic. We continue to support and service our current population of Piccolo Xpress and Piccolo Classic chemistry analyzers.
- **Veterinary Market:** We currently market the blood analysis system in the veterinary market under the name VetScan VS2. Through March 2006, we marketed the blood analysis system in the veterinary market as the VetScan, now referred to as the VetScan Classic. We continue to support and service our current population of VetScan VS2 and VetScan Classic chemistry analyzers.

In the veterinary market, we also offer the following products and services:

Hematology. We have marketed a veterinary hematology instrument under the name VetScan HM5 since September 2007. The VetScan HM5 offers a 22-parameter complete blood count (“CBC”) analysis, including a five-part differential cell counter specifically designed for veterinary applications. We also market the VetScan HM2, a veterinary hematology instrument that offers an 18-parameter CBC analysis, including a three-part white blood cell differential, marketed originally as the VetScan HMII. We currently purchase these hematology instruments from Diatron MI PLC (“Diatron”) of Budapest, Hungary. Through April 2004, we marketed a veterinary hematology instrument under the name VetScan HMT. We continue to support and service our current population of VetScan HM5, VetScan HM2, VetScan HMII and VetScan HMT hematology instruments. We also market reagent kits to be

used with our hematology instruments which we currently purchase from two suppliers: Clinical Diagnostic Solutions, Inc. and Diatron.

Coagulation and Specialty. We have marketed a veterinary coagulation and specialty analyzer under the name VetScan VSpro since January 2009. The VetScan VSpro assists in the diagnosis and evaluation of suspected bleeding disorders, toxicity/poisoning, evaluation of disseminated intravascular coagulation, hepatic disease and in monitoring therapy and the progression of disease states. The point-of-care coagulation and specialty analyzer is offered with a combination assay (PT/aPTT test cartridge) for canine and feline testing. In December 2010, we introduced the VetScan VSpro Fibrinogen Test, to provide quantitative in-vitro determination of fibrinogen levels in equine platelet poor plasma from a citrated stabilized whole blood sample. The VetScan VSpro Fibrinogen Test is designed for use with the VSpro coagulation and specialty analyzer. We currently purchase the coagulation and specialty analyzers and related cartridges from Scandinavian Micro Biodevices APS of Farum, Denmark (“SMB”). Additionally, in February 2011, we purchased a 15% equity ownership interest in SMB. See the “Investment in Unconsolidated Affiliate” section in Critical Accounting Policies, Estimates and Judgments for additional information.

Table of Contents

i-STAT. We have marketed i-STAT instruments and related cartridges in the veterinary market since fiscal 2010. The VetScan i-STAT 1 delivers blood gas, electrolyte, basic blood chemistry and hematology results in minutes from two drops of whole blood. In May 2009, we entered into an exclusive agreement with Abbott Point of Care Inc. (“Abbott”), granting us the right to sell and distribute Abbott’s i-STAT® 1 handheld instrument and associated consumables for blood gas, electrolyte, basic blood chemistry and immunoassay testing in the animal health care market worldwide. Our right to sell and distribute these products was initially non-exclusive, but became exclusive in all countries of the world, except for Japan, in November 2009. Our rights in Japan remain non-exclusive for the term of the agreement. The initial term of the agreement ends on December 31, 2014, and after this initial term, our agreement continues automatically for successive one-year periods unless terminated by either party.

Rapid Tests. In the veterinary market, we offer the following three VetScan Rapid Tests, which deliver easy to read results in approximately ten minutes, as described below.

- **Canine Heartworm Rapid Test:** In January 2009, we introduced the VetScan Canine Heartworm Rapid Test, a highly sensitive and specific test for the detection of *Dirofilaria immitis* in canine whole blood, serum or plasma. The lateral flow immunoassay technology in the canine heartworm rapid tests provides immediate results.
- **Canine Parvovirus Rapid Test:** In March 2011, we introduced the VetScan Canine Parvovirus Rapid Test Kit, a qualitative test for the detection of canine parvovirus antigen in feces. The VetScan Canine Parvovirus Rapid Test Kit uses a unique combination of monoclonal antibodies that provides the detection of parvovirus antigen, allowing the veterinarian to screen for and diagnose the infection.
- **Giardia Rapid Test:** In May 2011, we introduced the VetScan Giardia Rapid Test, which detects giardiasis, a gastrointestinal infection caused by the protozoan parasite *Giardia*. Symptoms of *Giardia* infection include diarrhea and weight loss and infection is also more common in younger pets.

Abaxis Veterinary Reference Laboratories. We began developing Abaxis Veterinary Reference Laboratories (“AVRL”), a full-service laboratory testing facility, based in Olathe, Kansas during fiscal 2011. In January 2011, we formed a strategic alliance with Kansas State University, K-State Veterinary Diagnostic Lab and a commercial affiliate of Kansas State University, the National Institute for Strategic Technology Acquisition and Commercialization, to enable AVRL to provide a full service commercial laboratory for veterinarians. In October 2011, AVRL began providing veterinary reference laboratory diagnostic and consulting services for veterinarians in the United States. AVRL also focuses on providing specialty and esoteric testing and analysis. This service complements our full suite of on-site laboratory instrumentation and rapid diagnostics for in hospital routine, critical care and emergency medicine laboratory needs.

Factors that May Impact Future Performance

Our industry is impacted by numerous competitive, regulatory and other significant factors. Our sales for any future periods are not predictable with a significant degree of certainty, and may depend on a number of factors outside of our control, including but not limited to inventory or timing considerations by our distributors. We generally operate with a limited order backlog because our products are typically shipped shortly after orders are received. Product sales in any quarter are generally dependent on orders booked and shipped in that quarter. As a result, any such revenue shortfall would negatively affect our operating results and financial condition. In addition, our sales may be adversely impacted by pricing pressure from competitors. Our ability to be consistently profitable will depend, in part, on our ability to increase the sales volumes of our Piccolo and VetScan products and to successfully compete with other competitors. We believe that period to period comparisons of our results of operations are not necessarily meaningful indicators of future results.

CRITICAL ACCOUNTING POLICIES, ESTIMATES AND JUDGMENTS

Our condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States and pursuant to the rules and regulations of the Securities and Exchange Commission. The preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and revenues and expenses during the reporting period. On an on-going basis, we evaluate our estimates and the sensitivity of these estimates to deviations in the assumptions used in making them. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. However, there can be no assurance that our actual results will not differ from these estimates.

We have identified the policies below as critical because they are not only important to understanding our financial condition and results of operations, but also because application and interpretation of these policies requires both judgment and estimates of matters that are inherently uncertain and unknown. Accordingly, actual results may differ materially from our estimates. The impact and any associated risks related to these policies on our business operations are discussed below. A more detailed discussion on the application of these and other accounting policies are included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2011.

Table of Contents

Revenue Recognition and Deferred Revenue. Our primary customers are distributors and direct customers in both the medical and veterinary markets. Revenues from product sales and services, net of estimated sales allowances, and rebates, are recognized when (i) evidence of an arrangement exists, (ii) upon shipment of the products or rendering of services to the customer, (iii) the sales price is fixed or determinable and (iv) collection of the resulting receivable is reasonably assured. Rights of return are not provided. Amounts collected in advance of revenue recognition are recorded as a current or non-current liability based on the time from the balance sheet date to the future date of revenue recognition. We recognize revenue associated with extended maintenance agreements ratably over the life of the contract.

We occasionally enter into multiple element revenue arrangements in which a customer may purchase a combination of instruments, consumables or extended maintenance agreements. Additionally, we provide incentives in the form of free goods or extended maintenance agreements to customers in connection with the sale of our instruments. Revenues from such sales are allocated separately to the instruments and incentives based on the relative selling price method. Revenue allocated to each element is then recognized when the basic revenue recognition criteria, as described above, is met for each element. Revenues allocated to incentives are deferred until the goods are shipped to the customer or are recognized ratably over the life of the maintenance contract.

We periodically offer trade-in programs to customers for trading in an existing instrument to purchase a new instrument and we will either provide incentives in the form of free goods or reduce the sales price of the instrument. These incentives in the form of free goods are recorded based on the relative selling price method according to the policies described above.

We periodically offer programs to customers whereby certain instruments are made available to customers for rent or on an evaluation basis. These programs typically require customers to purchase a minimum quantity of consumables during a specified period for which we recognize revenue on the related consumables according to the policies described above. Depending on the program offered, customers may purchase the instrument during the rental or evaluation period. Proceeds from such sale are recorded as revenue according to the policies described above. Rental income, if any, are also recorded as revenue according to the policies described above.

Royalties are typically based on licensees' net sales of products that utilize our technology and are recognized as earned in accordance with the contract terms when royalties from licensees can be reliably measured and collectibility is reasonably assured, such as upon the receipt of a royalty statement from the licensee. Our royalty revenue depends on the licensees' use of our technology, and therefore, may vary from period to period and impact our revenues during a quarter. On June 28, 2010, we notified Cepheid that Cepheid breached its license agreement with us due to Cepheid's discontinuation of license royalty payments. On October 1, 2010, we informed Cepheid that the breach had not been cured, and we terminated the entire license, as to all or any Cepheid products. As a result of the license termination, our development and licensing revenue was adversely and materially impacted in our consolidated financial statements during fiscal 2011. Also, we expect the license termination will adversely and materially impact development and licensing revenue in our consolidated financial statements in the foreseeable future.

Distributor and Customer Rebates. We offer distributor pricing rebates and customer incentives, such as cash rebates, from time to time. The distributor pricing rebates are offered to distributors upon meeting the sales volume requirements during a qualifying period and are recorded as a reduction to gross revenues during a qualifying period. Cash rebates are offered to distributors or customers who purchase certain products or instruments during a promotional period and are recorded as a reduction to gross revenues.

Allowance for Doubtful Accounts. We maintain an allowance for doubtful accounts based on our assessment of the collectibility of the amounts owed to us by our customers. In determining the amount of the allowance, we make judgments about the creditworthiness of customers which is mostly determined by the customer's payment history and

the outstanding period of accounts. We specifically identify amounts that we believe to be uncollectible and the allowance for doubtful accounts is adjusted accordingly. An additional allowance is recorded based on certain percentages of our aged receivables, using historical experience to estimate the potential uncollectible and our assessment of the general financial condition of our customer base. If our actual collections experience changes, revisions to our allowances may be required, which could adversely affect our operating income.

Fair Value Measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (“exit price”) in an orderly transaction between market participants at the measurement date. The Financial Accounting Standards Board (the “FASB”) Accounting Standards Codification (“ASC”) 820, “Fair Value Measurements and Disclosures,” establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:

Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities. As of December 31, 2011, our investments in cash equivalents, which we classified as available-for-sale, totaled \$1.2 million, using Level 1 inputs since these investments are traded in an active market. The valuations are based on quoted prices of the underlying security that are readily and regularly available in an active market, and accordingly, a significant degree of judgment is not required.

Table of Contents

Level 2: Directly or indirectly observable inputs as of the reporting date through correlation with market data, including quoted prices for similar assets and liabilities in active markets and quoted prices in markets that are not active. Level 2 also includes assets and liabilities that are valued using models or other pricing methodologies that do not require significant judgment since the input assumptions used in the models, such as interest rates and volatility factors, are corroborated by readily observable data from actively quoted markets for substantially the full term of the financial instrument. As of December 31, 2011, our available-for-sale investments in certificates of deposits, corporate bonds and municipal bonds, totaled \$8.3 million, using Level 2 inputs, based on market pricing and other observable market inputs for similar securities obtained from various third party data providers.

Level 3: Unobservable inputs that are supported by little or no market data and require the use of significant management judgment. These values are generally determined using pricing models for which the assumptions utilize management's estimates of market participant assumptions. As of December 31, 2011, we did not have any Level 3 financial assets or liabilities measured at fair value on a recurring basis.

Fair value is a market-based measure considered from the perspective of a market participant who holds the asset or owes the liability rather than an entity-specific measure. Therefore, even when market assumptions are not readily available, our own assumptions are developed to reflect those that market participants would use in pricing the asset or liability at the measurement date. At December 31, 2011, we also had \$44.3 million in investments classified as held-to-maturity and carried at amortized cost.

Investment in Unconsolidated Affiliate. In February 2011, we purchased a 15% equity ownership interest in Scandinavian Micro Biodevices APS ("SMB"), for \$2.8 million in cash. We use the equity method to account for our investment in this entity that we do not control, but where we have the ability to exercise significant influence. Equity method investments are recorded at original cost and adjusted periodically to recognize (1) our proportionate share of the investees' net income or losses after the date of investment, (2) additional contributions made and dividends or distributions received, and (3) impairment losses resulting from adjustments to net realizable value. We eliminate all intercompany transactions in accounting for our equity method investments. We record our proportionate share of the investees' net income or losses in "Interest and other income (expense), net" on the consolidated statements of income.

We assess the potential impairment of our equity method investments when indicators such as a history of operating losses, a negative earnings and cash flow outlook, and the financial condition and prospects for the investee's business segment might indicate a loss in value. We did not recognize any impairment loss on investment in unconsolidated affiliate during the three and nine months ended December 31, 2011.

Warranty Reserves. We provide for the estimated future costs to be incurred under our standard warranty obligation on our instruments. Our standard warranty obligation on instruments ranges from one to three years. The estimated contractual warranty obligation is recorded when the related revenue is recognized and any additional amount is recorded when such cost is probable and can be reasonably estimated. Cost of revenues reflects estimated warranty expense for instruments sold in the current period and any adjustments in estimated warranty expense for the installed base under our standard warranty obligation based on our quarterly evaluation of service experience. While we engage in product quality programs and processes, including monitoring and evaluating the quality of our suppliers, our estimated accrual for warranty exposure is based on our historical experience as to product failures, estimated product failure rates, estimated repair costs, material usage and freight incurred in repairing the instrument after failure and known design changes under the warranty plan.

A provision for defective reagent discs is recorded when the related sale is recognized and any additional amount is recorded when such cost is probable and can be reasonably estimated, at which time they are included in cost of revenues. The warranty cost includes the replacement costs and freight of a defective reagent disc.

As of December 31, 2011, our current portion of warranty reserves for instruments and reagent discs totaled \$1.1 million and our non-current portion of warranty reserves for instruments totaled \$482,000, which reflects our estimate of warranty obligations based on the estimated product failure rates, the number of instruments in standard warranty, estimated repair and related costs of instruments, and an estimate of defective reagent discs and replacement and related costs of a defective reagent disc.

Each quarter, we reevaluate our estimate of warranty reserves, including our assumptions. During the nine months ended December 31, 2011, we recorded an additional accrual to pre-existing warranties of \$257,000, which increased our warranty reserves and our cost of revenues, based on both historical and projected product performance rates.

Management continually evaluates the sufficiency of the warranty provisions and makes adjustments when necessary. If an unusual performance rate related to warranty claims is noted, an additional warranty accrual may be assessed and recorded when a failure event is probable and the cost can be reasonably estimated. We review the historical warranty cost trends and analyze the adequacy of the ending accrual balance of warranty reserves each quarter. The determination of warranty reserves requires us to make estimates of the estimated product failure rate, expected costs to repair or replace the instruments and to replace defective reagent discs under warranty. If actual repair or replacement costs of instruments or replacement costs of reagent discs differ significantly from our estimates, adjustments to cost of revenues may be required. Additionally, if factors change and we revise our assumptions on the product failure rate of instruments or reagent discs, then our warranty reserves and cost of revenues could be materially impacted in the quarter of revision, as well as in following quarters.

Table of Contents

Inventories. We state inventories at the lower of cost or market, cost being determined using standard costs which approximate actual costs using the first-in, first-out (FIFO) method. Inventories include material, labor and overhead. We establish provisions for excess, obsolete and unusable inventories after evaluation of future demand and market conditions. If future demand or actual market conditions are less favorable than those estimated by management or if a significant amount of the material were to become unusable, additional inventory write-downs may be required, which would have a negative effect on our operating income.

Valuation of Long-Lived Assets. We evaluate the carrying value of our long-lived assets, such as property and equipment and amortized intangible assets, whenever events or changes in business circumstances or our planned use of long-lived assets indicate that the carrying amount of an asset may not be fully recoverable or their useful lives are no longer appropriate. We look to current and future profitability, as well as current and future undiscounted cash flows, excluding financing costs, as primary indicators of recoverability. An impairment loss would be recognized when the sum of the undiscounted future net cash flows expected to result from the use of the asset and its eventual disposal is less than the carrying amount. If impairment is determined to exist, any related impairment loss is calculated based on fair value and long-lived assets are written down to their respective fair values. We did not recognize any impairment charges on long-lived assets during the three or nine months ended December 31, 2011.

Income Taxes. We account for income taxes using the liability method under which deferred tax assets and liabilities are determined based on the differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amounts expected to be recovered.

We recognize and measure benefits for uncertain tax positions using a two-step approach. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of evidence indicates that it is more likely than not that the tax position will be sustained upon audit, including resolution of any related appeals or litigation processes. For tax positions that are more likely than not to be sustained upon audit, the second step is to measure the tax benefit as the largest amount that is more than 50 percent likely to be realized upon settlement. Significant judgment is required to evaluate uncertain tax positions. At December 31, 2011 and 2010, we had no uncertain tax positions. Our policy is to include interest and penalties related to gross unrecognized tax benefits within our provision for income taxes. During the three and nine months ended December 31, 2011 and 2010, we did not recognize any interest or penalties related to uncertain tax positions in the condensed consolidated statements of income, and at December 31, 2011 and 2010, we had no accrued interest or penalties.

Share-Based Compensation Expense. We recognize share-based compensation expense, net of an estimated forfeiture rate, over the requisite service period of the award to employees and directors.

There were no stock options granted since the beginning of fiscal 2007 and we did not grant stock options during the nine months ended December 31, 2011. For restricted stock units, share-based compensation expense is based on the fair value of our stock at the grant date and recognized net of an estimated forfeiture rate, over the requisite service period of the award. As a result, if factors change and we use different assumptions, our share-based compensation expense could be materially different in the future.

As required by fair value provisions of share-based compensation, employee share-based compensation expense recognized is calculated over the requisite service period of the awards and reduced for estimated forfeitures. The forfeiture rate is estimated based on historical data of our share-based compensation awards that are granted and cancelled prior to vesting and upon historical experience of employee turnover. Changes in estimated forfeiture rates and differences between estimated forfeiture rates and actual experience may result in significant, unanticipated

increases or decreases in share-based compensation expense from period to period. To the extent we revise our estimate of the forfeiture rate in the future, our share-based compensation expense could be materially impacted in the quarter of revision, as well as in following quarters.

Share-based compensation expense resulted in a material impact on our earnings per share and on our condensed consolidated financial statements for fiscal 2011 and during the three and nine months ended December 31, 2011. The impact of share-based compensation expense on our condensed consolidated financial results is disclosed in Note 11, "Share-Based Compensation" in the Notes to Condensed Consolidated Financial Statements in this Quarterly Report on Form 10-Q. We expect that share-based compensation will materially impact our consolidated financial statements in the foreseeable future.

RESULTS OF OPERATIONS

Abaxis develops, manufactures, markets and sells portable blood analysis systems for use in the human or veterinary patient-care setting to provide clinicians with rapid blood constituent measurements. In October 2011, Abaxis began providing veterinary reference laboratory diagnostic and consulting services for veterinarians. We operate in two segments: (i) the medical market and (ii) the veterinary market. See "Segment Results" in this section for a detailed discussion.

Table of Contents

Total Revenues

Revenues by Geographic Region and by Product and Service Category. Revenues by geographic region based on customer location and revenues by product and service category during the three and nine months ended December 31, 2011 and 2010 were as follows (in thousands, except percentages):

Revenues by Geographic Region	Three Months Ended December 31,				Change		Nine Months Ended December 31,				Change	
	2011	2010	Increase/ (Decrease)	Percent Change			2011	2010	Increase/ (Decrease)	Percent Change		
North America	\$ 31,847	\$ 30,068	\$ 1,779	6%			\$ 93,540	\$ 87,385	\$ 6,155	7%		
Percentage of total revenues	84	%	84	%			82	%	82	%		
Europe	4,516	4,508	8	<1%			16,326	14,838	1,488	10%		
Percentage of total revenues	12	%	13	%			14	%	14	%		
Asia Pacific and rest of the world	1,487	1,330	157	12%			4,012	3,913	99	3%		
Percentage of total revenues	4	%	3	%			4	%	4	%		
Total revenues	\$ 37,850	\$ 35,906	\$ 1,944	5%			\$ 113,878	\$ 106,136	\$ 7,742	7%		

Revenues by Product and Service Category	Three Months Ended December 31,				Change		Nine Months Ended December 31,				Change	
	2011	2010	Increase/ (Decrease)	Percent Change			2011	2010	Increase/ (Decrease)	Percent Change		
Instruments(1)	\$ 9,079	\$ 9,289	\$ (210)	(2)%			\$ 25,364	\$ 24,256	\$ 1,108	5%		
Percentage of total revenues	24	%	26	%			22	%	23	%		
Consumables(2)	26,808	24,509	2,299	9%			83,019	75,136	7,883	10%		
Percentage of total revenues	71	%	68	%			73	%	71	%		
Other products and services(3)	1,925	1,753	172	10%			5,372	5,558	(186)	(3)%		
Percentage of total revenues	5	%	5	%			5	%	5	%		
Product and service revenues, net	37,812	35,551	2,261	6%			113,755	104,950	8,805	8%		
Percentage of total revenues	100	%	99	%			100	%	99	%		
Development and licensing revenue	38	355	(317)	(89)%			123	1,186	(1,063)	(90)%		
Percentage of total revenues	<1%	1	%				<1%	1	%			
Total revenues	\$ 37,850	\$ 35,906	\$ 1,944	5%			\$ 113,878	\$ 106,136	\$ 7,742	7%		

- (1) Instruments include chemistry analyzers, hematology instruments, VSpro coagulation and specialty analyzers and i-STAT analyzers.
- (2) Consumables include reagent discs, hematology reagent kits, VSpro coagulation and specialty cartridges, i-STAT cartridges and rapid tests.
- (3) Other products and services include veterinary reference laboratory diagnostic and consulting services.

Three Months Ended December 31, 2011 Compared to Three Months Ended December 31, 2010

North America. During the three months ended December 31, 2011, total revenues in North America increased by 6%, or \$1.8 million, as compared to the three months ended December 31, 2010. The change in total revenues in North America was primarily attributable to the following:

- Total sales of our Piccolo chemistry analyzers and medical reagent discs in North America (excluding sales to the U.S. government) increased by 11%, or \$556,000, primarily due to an increase in the sales volume of medical reagent discs to various distributors resulting from higher sales to end users.
- Total sales of our Piccolo chemistry analyzers and medical reagent discs to the U.S. government decreased by 59%, or \$957,000, primarily due to a decrease in the U.S. Military's needs for our products as a result of U.S. troops leaving Iraq in 2011.
- Total sales of our VetScan chemistry analyzers and veterinary reagent discs in North America increased by 9%, or \$1.3 million, primarily attributable to an increase in the sales volume of veterinary reagent discs resulting from an expanded installed base of our VetScan chemistry analyzers, partially offset by a net decrease in the sales volume of VetScan chemistry analyzers due in part to lower sales to various distributors.
- Total sales of our VetScan hematology instruments and hematology reagent kits in North America decreased by 2%, or \$78,000, primarily attributable to a decrease in the sales volume of VetScan hematology instruments due in part to lower sales to various distributors, partially offset by an increase in units of hematology reagent kits sold resulting from an expanded installed base of our VetScan hematology instruments.
- Total sales from our VSpro coagulation and specialty analyzers and related consumables, i-STAT analyzers and related consumables and rapid tests in North America increased by 29%, or \$1.2 million, primarily due to an increase in the sales volume of rapid tests, which includes our Canine Heartworm Rapid Test, introduced in January 2009, our Canine Parvovirus Rapid Test, introduced in March 2011 and our Giardia Rapid Test, introduced in May 2011.
- Total revenues from development and licensing in North America decreased by 89%, or \$317,000, primarily based on a licensee's discontinuation of license royalty payments. On June 28, 2010, we notified Cepheid that Cepheid breached its license agreement with us due to Cepheid's discontinuation of license royalty payments. On October 1, 2010, we informed Cepheid that the breach had not been cured, and we terminated the entire license, as to all or any Cepheid products. For further information, see Note 9 of the Notes to Condensed Consolidated Financial Statements contained in this Quarterly Report on Form 10-Q.

Table of Contents

Europe. During the three months ended December 31, 2011, total revenues in Europe were flat as compared to the three months ended December 31, 2010. Revenues from Piccolo chemistry analyzers and medical reagent discs increased by 43%, or \$469,000, primarily due to an increase in the sales volume of medical reagent discs to various distributors. Revenues from veterinary instruments increased by 37%, or \$332,000, primarily due to an increase in the sales volume of VetScan chemistry analyzers to various distributors. Net revenues in Europe were partially offset by a decrease in sales of veterinary reagent discs by 40%, or \$899,000, primarily due to the timing of inventory purchases by a distributor.

Asia Pacific and rest of the world. During the three months ended December 31, 2011, total revenues in Asia Pacific and rest of the world increased by 12%, or \$157,000, as compared to the three months ended December 31, 2010, primarily due to a net increase in revenues from veterinary instruments of 32%, or \$103,000, primarily resulting from an increase in the sales volume of VetScan chemistry analyzers to various distributors.

Significant concentration. During the three months ended December 31, 2011, one distributor in the United States, Animal Health International, accounted for 15% of our total worldwide revenues. Animal Health International was formed in 2011 from two animal health companies, which included Walco International, Inc., d/b/a DVM Resources. There were no distributors or direct customers that accounted for 10% or more of our total worldwide revenues during the three months ended December 31, 2010.

Nine Months Ended December 31, 2011 Compared to Nine Months Ended December 31, 2010

North America. During the nine months ended December 31, 2011, total revenues in North America increased by 7%, or \$6.2 million, as compared to the nine months ended December 31, 2010. The change in total revenues in North America was primarily attributable to the following:

- Total sales of our Piccolo chemistry analyzers and medical reagent discs in North America (excluding sales to the U.S. government) increased by 11%, or \$1.5 million, primarily due to an increase in the sales volume of medical reagent discs to various distributors resulting from higher sales to end users.
- Total sales of our Piccolo chemistry analyzers and medical reagent discs to the U.S. government decreased by 14%, or \$452,000, primarily due to a decrease in the U.S. Military's needs for our products as a result of U.S. troops leaving Iraq in 2011.
- Total sales of our VetScan chemistry analyzers and veterinary reagent discs in North America increased by 7%, or \$3.1 million, primarily attributable to (a) an increase in the sales volume of VetScan chemistry analyzers due in part to additional sales personnel, (b) an increase in the sales volume of veterinary reagent discs resulting from an expanded installed base of our VetScan chemistry analyzers and (c) higher average selling prices of veterinary reagent discs.
- Total sales of our VetScan hematology instruments and hematology reagent kits in North America increased by 9%, or \$915,000, primarily due to an increase in units of hematology reagent kits sold resulting from an expanded installed base of our VetScan hematology instruments.
- Total sales from our VSpro coagulation and specialty analyzers and related consumables, i-STAT analyzers and related consumables and rapid tests in North America increased by 19%, or \$2.4 million, primarily attributable to (a) an increase in the sales volume of i-STAT analyzers due in part to additional sales personnel and (b) an increase in the sales volume of rapid tests, which includes our Canine Heartworm Rapid Test, introduced in January 2009, our Canine Parvovirus Rapid Test, introduced in March 2011 and our Giardia Rapid Test, introduced in May 2011.

- Total revenues from development and licensing in North America decreased by 90%, or \$1.1 million, primarily based on a licensee's discontinuation of license royalty payments. On June 28, 2010, we notified Cepheid that Cepheid breached its license agreement with us due to Cepheid's discontinuation of license royalty payments. On October 1, 2010, we informed Cepheid that the breach had not been cured, and we terminated the entire license, as to all or any Cepheid products. For further information, see Note 9 of the Notes to Condensed Consolidated Financial Statements contained in this Quarterly Report on Form 10-Q.

Table of Contents

Europe. During the nine months ended December 31, 2011, total revenues in Europe increased by 10%, or \$1.5 million, as compared to the nine months ended December 31, 2010. Revenues from Piccolo chemistry analyzers and medical reagent discs increased by 6%, or \$200,000, primarily due to an increase in the sales volume of medical reagent discs to various distributors. Revenues from veterinary instruments increased by 25%, or \$710,000, primarily due to an increase in the sales volume of VetScan chemistry analyzers to various distributors. Revenues from veterinary reagent discs increased by 5%, or \$410,000, primarily attributable to higher Euro exchange rates during the first quarter of fiscal 2012, partially offset by a decrease in the sales volume primarily due to the timing of inventory purchases by a distributor.

Asia Pacific and rest of the world. During the nine months ended December 31, 2011, total revenues in Asia Pacific and rest of the world increased by 3%, or \$99,000, as compared to the nine months ended December 31, 2010, primarily due to an increase in total revenues from VetScan chemistry analyzers and veterinary reagent discs of 5%, or \$104,000.

Significant concentration. During the nine months ended December 31, 2011, one distributor in the United States, Animal Health International, accounted for 12% of our total worldwide revenues. Animal Health International was formed in 2011 from two animal health companies, which included Walco International, Inc., d/b/a DVM Resources. There were no distributors or direct customers that accounted for 10% or more of our total worldwide revenues during the nine months ended December 31, 2010.

Segment Results

Three Months Ended December 31, 2011 Compared to Three Months Ended December 31, 2010

The following table presents revenues, cost of revenues, gross profit and percentage of revenues by operating segments and from certain unallocated items for the three months ended December 31, 2011 and 2010 (in thousands, except percentages):

	2011	Percent of Revenues(1)	Three Months Ended December 31, 2010	Percent of Revenues(1)	Change Increase/ (Decrease)	Percent Change
Revenues:						
Medical Market	\$ 8,147	100%	\$ 8,126	100%	\$ 21	<1%
Percentage of total revenues	22	%	23	%		
Veterinary Market	28,467	100%	26,283	100%	2,184	8%
Percentage of total revenues	75	%	73	%		
Other(2)	1,236		1,497		(261)	(17)%
Percentage of total revenues	3	%	4	%		
Total revenues	37,850		35,906		1,944	5%
Cost of revenues:						
Medical Market	3,514	43%	3,721	46%	(207)	(6)%
Veterinary Market	12,472	44%	11,153	42%	1,319	12%
Other(2)	1,386		1,223		163	13%
Total cost of revenues	17,372		16,097		1,275	8%

Gross profit:						
Medical Market	4,633	57%	4,405	54%	228	5%
Veterinary Market	15,995	56%	15,130	58%	865	6%
Other(2)	(150)		274		(424)	(155)%
Gross profit	\$ 20,478		\$ 19,809		\$ 669	3%

(1) The percentages reported are based on our revenues by operating segment.

(2) Represents unallocated items, not specifically identified to any particular business segment.

Medical Market

Revenues for Medical Market Segment

During the three months ended December 31, 2011, total revenues in the medical market was flat, as compared to the three months ended December 31, 2010. Total revenues from Piccolo chemistry analyzers decreased by 14%, or \$376,000, during the three months ended December 31, 2011, as compared to the same period in fiscal 2011, primarily due to a decrease in the U.S. Military's needs as a result of U.S. troops leaving Iraq in 2011. Total revenues from medical reagent discs increased by 9%, or \$442,000, during the three months ended December 31, 2011, as compared to the same period in fiscal 2011, primarily attributable to (a) an increase in the sales volume to various distributors in North America resulting from higher sales to end users and (b) an increase in the sales volume to various distributors in Europe. The net increase in revenues from medical reagent discs was partially offset by a decrease in the U.S. Military's needs as a result of U.S. troops leaving Iraq in 2011.

Table of Contents

Gross Profit for Medical Market Segment

Gross profit for the medical market segment increased by 5%, or \$228,000, during the three months ended December 31, 2011, as compared to the three months ended December 31, 2010. Gross profit percentages for the medical market segment during the three months ended December 31, 2011 and 2010 were 57% and 54%, respectively. In absolute dollars and as a percentage, the increase in gross profit for the medical market segment was primarily due to (a) an increase in the sales volume of medical reagent discs and (b) lower manufacturing costs on medical reagent discs. The increase in gross profit was partially offset by lower average selling prices of Piccolo chemistry analyzers.

Veterinary Market

Revenues for Veterinary Market Segment

During the three months ended December 31, 2011, total revenues in the veterinary market increased by 8%, or \$2.2 million, as compared to the three months ended December 31, 2010. Total revenues from veterinary instruments increased by 2%, or \$166,000, during the three months ended December 31, 2011, as compared to the same period in fiscal 2011, primarily attributable to an increase in the sales volume of VetScan chemistry analyzers to various distributors in Europe, Asia Pacific and rest of the world, partially offset by a decrease in the sales volume of VetScan chemistry analyzers and VetScan hematology instruments, both due in part to lower sales to various distributors in North America.

Total revenues from consumables in the veterinary market increased by 10%, or \$1.9 million, during the three months ended December 31, 2011, as compared to the same period in fiscal 2011, primarily attributable to (a) an increase in the sales volume of veterinary reagent discs resulting from an expanded installed base of our VetScan chemistry analyzers in North America, (b) an increase in units of hematology reagent kits sold resulting from an expanded installed base of our VetScan hematology instruments in North America and (c) an increase in the sales volume in North America of rapid tests, which includes our Canine Heartworm Rapid Test, introduced in January 2009, our Canine Parvovirus Rapid Test, introduced in March 2011 and our Giardia Rapid Test, introduced in May 2011. The net increase in revenues from consumables was partially offset by a decrease in sales of veterinary reagent discs in Europe primarily due to the timing of inventory purchases by a distributor.

Gross Profit for Veterinary Market Segment

Gross profit for the veterinary market segment increased by 6%, or \$865,000, during the three months ended December 31, 2011, as compared to the three months ended December 31, 2010. Gross profit percentages for the veterinary market segment during the three months ended December 31, 2011 and 2010 were 56% and 58%, respectively. In absolute dollars, the increase in gross profit for the veterinary market segment was primarily attributable to (a) higher average selling prices of veterinary reagent discs, (b) lower manufacturing costs on veterinary discs and (c) an increase in the sales volume of our rapid tests. The increase in gross profit was partially offset by an increase in costs of services provided by AVRL beginning in the third quarter of fiscal 2012. As a percentage, the decrease in gross profit was primarily due to (a) an increase in the sales volume of our OEM supplied products, which have a lower margin contribution and (b) an increase in costs of services provided by AVRL beginning in the third quarter of fiscal 2012.

Other

Gross profit in our other category decreased by 155%, or \$424,000, during the three months ended December 31, 2011, as compared to the three months ended December 31, 2010, primarily attributable to (a) a decrease in development and licensing revenue based on a licensee's discontinuation of license royalty payments and (b) an

increase in deferred revenue related to extended maintenance contracts offered to customers from time to time as incentives in the form of free goods in connection with the sale of our products.

Table of Contents

Nine Months Ended December 31, 2011 Compared to Nine Months Ended December 31, 2010

The following table presents revenues, cost of revenues, gross profit and percentage of revenues by operating segments and from certain unallocated items for the nine months ended December 31, 2011 and 2010 (in thousands, except percentages):

	2011	Percent of Revenues(1)	Nine Months Ended December 31, 2010	Percent of Revenues(1)	Change Increase/(Decrease)	Percent Change
Revenues:						
Medical Market	\$ 22,636	100%	\$ 21,421	100%	\$ 1,215	6%
Percentage of total revenues	20	%	20	%		
Veterinary Market	87,684	100%	79,750	100%	7,934	10%
Percentage of total revenues	77	%	75	%		
Other(2)	3,558		4,965		(1,407)	(28)%
Percentage of total revenues	3	%	5	%		
Total revenues	113,878		106,136		7,742	7%
Cost of revenues:						
Medical Market	10,180	45%	9,927	46%	253	3%
Veterinary Market	37,893	43%	33,209	42%	4,684	14%
Other(2)	4,083		3,657		426	12%
Total cost of revenues	52,156		46,793		5,363	11%
Gross profit:						
Medical Market	12,456	55%	11,494	54%	962	8%
Veterinary Market	49,791	57%	46,541	58%	3,250	7%
Other(2)	(525)		1,308		(1,833)	(140)%
Gross profit	\$ 61,722		\$ 59,343		\$ 2,379	4%

(1) The percentages reported are based on our revenues by operating segment.

(2) Represents unallocated items, not specifically identified to any particular business segment.

Medical Market**Revenues for Medical Market Segment**

During the nine months ended December 31, 2011, total revenues in the medical market increased by 6%, or \$1.2 million, as compared to the nine months ended December 31, 2010. Total revenues from Piccolo chemistry analyzers decreased by 8%, or \$509,000, during the nine months ended December 31, 2011, as compared to the same period in fiscal 2011, primarily due to a decrease in the U.S. Military's needs as a result of U.S. troops leaving Iraq in 2011. Total revenues from medical reagent discs increased by 12%, or \$1.8 million, during the nine months ended December 31, 2011, as compared to the same period in fiscal 2011, primarily attributable to (a) an increase in the sales volume to various distributors in North America resulting from higher sales to end users and (b) an increase in the sales volume to various distributors in Europe.

Gross Profit for Medical Market Segment

Gross profit for the medical market segment increased by 8%, or \$962,000, during the nine months ended December 31, 2011, as compared to the nine months ended December 31, 2010. Gross profit percentages for the medical market segment during the nine months ended December 31, 2011 and 2010 were 55% and 54%, respectively. In absolute dollars, the increase in gross profit for the medical market segment was primarily attributable to (a) an increase in the sales volume of medical reagent discs and (b) lower manufacturing costs on medical reagent discs. The increase in gross profit was partially offset by lower average selling prices and a decrease in the sales volume of Piccolo chemistry analyzers.

Veterinary Market

Revenues for Veterinary Market Segment

During the nine months ended December 31, 2011, total revenues in the veterinary market increased by 10%, or \$7.9 million, as compared to the nine months ended December 31, 2010. Total revenues from veterinary instruments increased by 9%, or \$1.6 million, during the nine months ended December 31, 2011, as compared to the same period in fiscal 2011, primarily attributable to (a) an increase in the sales volume of VetScan chemistry analyzers and i-STAT analyzers in North America, both due in part to additional sales personnel and (b) an increase in the sales volume of VetScan chemistry analyzers to various distributors in Europe.

Total revenues from consumables in the veterinary market increased by 10%, or \$6.1 million, during the nine months ended December 31, 2011, as compared to the same period in fiscal 2011, primarily attributable to (a) an increase in the sales volume of veterinary reagent discs in North America resulting from an expanded installed base of our VetScan chemistry analyzers, (b) higher average selling prices of veterinary reagent discs in North America, (c) higher Euro exchange rates of our veterinary reagent discs sold in Europe during the first quarter of fiscal 2012, (d) an increase in units of hematology reagent kits sold in North America resulting from an expanded installed base of our VetScan hematology instruments and (e) an increase in the sales volume in North America of rapid tests, which includes our Canine Heartworm Rapid Test, introduced in January 2009, our Canine Parvovirus Rapid Test, introduced in March 2011 and our Giardia Rapid Test, introduced in May 2011. The net increase in revenues from consumables was partially offset by a decrease in the sales volume of veterinary reagent discs in Europe primarily due to the timing of inventory purchases by a distributor.

Table of Contents

Gross Profit for Veterinary Market Segment

Gross profit for the veterinary market segment increased by 7%, or \$3.3 million, during the nine months ended December 31, 2011, as compared to the nine months ended December 31, 2010. Gross profit percentages for the veterinary market segment during the nine months ended December 31, 2011 and 2010 were 57% and 58%, respectively. In absolute dollars, the increase in gross profit for the veterinary market segment was primarily due to (a) an increase in the sales volume of VetScan chemistry analyzers, veterinary reagent discs, hematology reagent kits and rapid tests, (b) higher average selling prices of veterinary reagent discs and (c) lower manufacturing costs of veterinary reagent discs. The increase in gross profit was partially offset by (a) higher manufacturing and repair costs on VetScan hematology instruments and (b) an increase in costs of services provided by AVRL beginning in the third quarter of fiscal 2012. As a percentage, the decrease in gross profit was primarily due to (a) an increase in freight costs to ship products, (b) an increase in the sales volume of our OEM supplied products, which have a lower margin contribution and (c) an increase in costs of services provided by AVRL beginning in the third quarter of fiscal 2012.

Other

Gross profit in our other category decreased by 140%, or \$1.8 million, during the nine months ended December 31, 2011, as compared to the nine months ended December 31, 2010, primarily attributable to (a) a decrease in development and licensing revenue based on a licensee's discontinuation of license royalty payments, (b) an increase in deferred revenue related to extended maintenance contracts offered to customers from time to time as incentives in the form of free goods in connection with the sale of our products and (c) an increase in costs of materials and overhead allocations on facilities, both related to our instrument repair and support center, which are not allocated to a particular segment.

Cost of Revenues

The following sets forth our cost of revenues for the periods indicated (in thousands, except percentages):

	Three Months Ended December 31,				Nine Months Ended December 31,			
	2011		2010		2011		2010	
				Change Increase/ Percent (Decrease)Change				Change Increase/ Percent (Decrease)Change
Cost of revenues	\$ 17,372		\$ 16,097	\$ 1,275 8 %	\$ 52,156		\$ 46,793	\$ 5,363 11 %
Percentage of total revenues	46	%	45	%	46	%	44	%

Cost of revenues includes material, costs associated with manufacturing, assembly, packaging, warranty repairs, test and quality assurance for our instruments and consumables and manufacturing overhead, including costs of personnel and equipment associated with manufacturing support. Beginning in the third quarter of fiscal 2012, cost of revenues includes cost of services for veterinary reference laboratory diagnostic and consulting services provided by AVRL.

Three and Nine Months Ended December 31, 2011 Compared to Three and Nine Months Ended December 31, 2010

The increase in cost of revenues, in absolute dollars, during the three months ended December 31, 2011, as compared to the three months ended December 31, 2010, was primarily due to (a) an increase in the sales volume of medical reagent discs, (b) an increase in the sales volume of OEM supplied products, (c) an increase in freight costs to ship products and (d) costs of services provided by AVRL beginning in the third quarter of fiscal 2012. The increase in cost of revenues was partially offset by lower manufacturing costs of reagent discs.

The increase in cost of revenues, in absolute dollars, during the nine months ended December 31, 2011, as compared to the nine months ended December 31, 2010, was primarily due to (a) an increase in the sales volume of medical reagent discs, (b) an increase in the sales volume of VetScan chemistry analyzers and OEM supplied products, (c) higher manufacturing and repair costs of instruments, (d) higher costs on VetScan hematology instruments due to the Euro exchange rate, (e) an increase in freight costs to ship products and (f) costs of services provided by AVRL beginning in the third quarter of fiscal 2012. The increase in cost of revenues was partially offset by lower manufacturing costs of reagent discs.

Table of Contents

Gross Profit

The following sets forth our gross profit for the periods indicated (in thousands, except percentages):

	Three Months Ended December 31,		Change Increase/ Percent (Decrease) Change			Nine Months Ended December 31,		Change Increase/ Percent (Decrease) Change	
	2011	2010				2011	2010		
Total gross profit	\$20,478	\$19,809	\$669	3 %		\$61,722	\$59,343	\$2,379	4 %
Total gross margin	54 %	55 %				54 %	56 %		

Three and Nine Months Ended December 31, 2011 Compared to Three and Nine Months Ended December 31, 2010

Gross profit during the three months ended December 31, 2011 increased 3%, or \$669,000, as compared to the three months ended December 31, 2010, primarily attributable to (a) an increase in the sales volume of medical reagent discs, (b) higher average selling prices of veterinary reagent discs, (c) lower manufacturing costs on medical and veterinary discs and (d) an increase in the sales volume of our rapid tests. The increase in gross profit was partially offset by (a) lower average selling prices of Piccolo chemistry analyzers, (b) an increase in costs of services provided by AVRL beginning in the third quarter of fiscal 2012, (c) a decrease in development and licensing revenue based on a licensee's discontinuation of license royalty payments and (d) an increase in deferred revenue related to extended maintenance contracts offered to customers from time to time as incentives in the form of free goods in connection with the sale of our products. As a percentage, the decrease in gross profit was primarily due to (a) an increase in the sales volume of our OEM supplied products, which have a lower margin contribution and (b) an increase in costs of services provided by AVRL beginning in the third quarter of fiscal 2012.

Gross profit during the nine months ended December 31, 2011 increased 4%, or \$2.4 million, as compared to the nine months ended December 31, 2010, primarily attributable to (a) an increase in the sales volume of VetScan chemistry analyzers, (b) an increase in the sales volume of medical and veterinary reagent discs, (c) an increase in the sales volume of hematology reagent kits, (d) higher average selling prices of veterinary reagent discs and (e) lower manufacturing costs on medical and veterinary reagent discs. The increase in gross profit was partially offset by (a) higher manufacturing and repair costs on instruments, (b) an increase in costs of services provided by AVRL beginning in the third quarter of fiscal 2012, (c) a decrease in development and licensing revenue based on a licensee's discontinuation of license royalty payments, (d) an increase in deferred revenue related to extended maintenance contracts offered to customers from time to time as incentives in the form of free goods in connection with the sale of our products and (e) an increase in costs of materials and overhead allocations on facilities, both related to our instrument repair and support center. As a percentage, the decrease in gross profit was primarily due to (a) an increase in freight costs to ship products, (b) an increase in the sales volume of our OEM supplied products, which have a lower margin contribution and (c) an increase in costs of services provided by AVRL beginning in the third quarter of fiscal 2012.

Research and Development

The following sets forth our research and development expenses for the periods indicated (in thousands, except percentages):

	Three Months Ended December 31,		Change Increase/ Percent (Decrease) Change			Nine Months Ended December 31,		Change Increase/ Percent (Decrease) Change	
	2011	2010				2011	2010		

Research and development expenses	\$ 2,634	\$ 2,947	\$(313)	(11)%	\$ 9,096	\$ 9,321	\$(225)	(2)%
Percentage of total revenues	7	%	8	%	8	%	9	%

Research and development expenses consist of personnel costs (including salaries, benefits and share-based compensation expense), consulting expenses and materials and related expenses associated with the development of new tests and test methods, clinical trials, product improvements and optimization and enhancement of existing products.

Three and Nine Months Ended December 31, 2011 Compared to Three and Nine Months Ended December 31, 2010

The decrease in research and development expenses, in absolute dollars, during the three and nine months ended December 31, 2011, as compared to the three and nine months ended December 31, 2010, was primarily due to lower expenses related to new product development and enhancement of existing products and clinical trials. Research and development expenses are based on the project activities planned and the level of spending depends on budgeted expenditures. The projects primarily relate to new product development in both the medical and veterinary markets and costs related to compliance with FDA regulations and clinical trials. Share-based compensation expense during the three months ended December 31, 2011 and 2010 was \$226,000 and \$195,000, respectively, and during the nine months ended December 31, 2011 and 2010 was \$641,000 and \$684,000, respectively.

We anticipate research and development expenses for fiscal 2012 to remain consistent as a percentage of total revenues, as we develop new products for both the medical and veterinary markets. There can be no assurance, however, that we will undertake such research and development activities in future periods or, if we do, that such activities will be successful or cost effective.

Table of Contents

Sales and Marketing

The following sets forth our sales and marketing expenses for the periods indicated (in thousands, except percentages):

	Three Months Ended December 31,				Nine Months Ended December 31,			
			Change				Change	
	2011	2010	Increase/ (Decrease)	Percent Change	2011	2010	Increase/ (Decrease)	Percent Change
Sales and marketing expenses	\$9,927	\$8,208	\$1,719	21 %	\$28,414	\$25,249	\$3,165	13 %
Percentage of total revenues	26 %	23 %			25 %	24 %		

Sales and marketing expenses consist of personnel costs (including salaries, benefits and share-based compensation expense), commissions and travel-related expenses for personnel engaged in selling, costs associated with advertising, lead generation, marketing programs, trade shows, services related to customer and technical support and costs associated with advertising and marketing of AVRL.

Three and Nine Months Ended December 31, 2011 Compared to Three and Nine Months Ended December 31, 2010

The increase in sales and marketing expenses, in absolute dollars, during the three and nine months ended December 31, 2011, as compared to the three and nine months ended December 31, 2010, was primarily due to (a) increased personnel-related costs resulting from an increase in headcount to support the growth in our veterinary market in North America and (b) increased promotional and marketing related spending in our veterinary market in North America. Share-based compensation expense during the three months ended December 31, 2011 and 2010 was \$475,000 and \$365,000, respectively, and during the nine months ended December 31, 2011 and 2010 was \$1.4 million and \$1.1 million, respectively.

General and Administrative

The following sets forth our general and administrative expenses for the periods indicated (in thousands, except percentages):

	Three Months Ended December 31,				Nine Months Ended December 31,			
			Change				Change	
	2011	2010	Increase/ (Decrease)	Percent Change	2011	2010	Increase/ (Decrease)	Percent Change
General and administrative expenses	\$3,280	\$2,820	\$460	16 %	\$11,194	\$7,596	\$3,598	47 %
Percentage of total revenues	9 %	8 %			10 %	7 %		

General and administrative expenses consist of personnel costs (including salaries, benefits and share-based compensation expense), and expenses for outside professional services related to general corporate functions, including accounting and legal, and other general and administrative expenses.

Three and Nine Months Ended December 31, 2011 Compared to Three and Nine Months Ended December 31, 2010

The increase in general and administrative expenses, in absolute dollars, during the three months ended December 31, 2011, as compared to the three months ended December 31, 2010, was primarily due to an increase in legal expenses primarily related to pursuing a patent infringement case and compliance in an investigation by the United States Federal Trade Commission of a competitor. Share-based compensation expense during the three months ended December 31, 2011 and 2010 was \$624,000 and \$570,000, respectively.

The increase in general and administrative expenses, in absolute dollars, during the nine months ended December 31, 2011, as compared to the nine months ended December 31, 2010, was primarily due to (a) an increase of \$1.5 million in legal expenses, primarily related to pursuing a patent infringement case and compliance in an investigation by the United States Federal Trade Commission of a competitor and (b) an increase of \$1.6 million related to start-up costs to develop AVRIL during the first and second quarters of fiscal 2012, which AVRIL began providing services starting in the third quarter of fiscal 2012. Share-based compensation expense during the nine months ended December 31, 2011 and 2010 was \$1.5 million and \$1.2 million, respectively.

Interest and Other Income (Expense), Net

The following sets forth our interest and other income (expense), net, for the periods indicated (in thousands):

	Three Months Ended December 31,		Change Increase/ (Decrease)	Nine Months Ended December 31,		Change Increase/ (Decrease)
	2011	2010		2011	2010	
Interest and other income (expense), net	\$ (91)	\$ 46	\$(137)	\$ 259	\$ 698	\$(439)

Interest and other income (expense), net consists primarily of interest earned on cash and cash equivalents and investments, foreign currency exchange gains and losses and our equity in net income and loss of an unconsolidated affiliate.

Table of Contents

Three and Nine Months Ended December 31, 2011 Compared to Three and Nine Months Ended December 31, 2010

The decrease in interest and other income (expense), net, during the three months ended December 31, 2011, as compared to the three months ended December 31, 2010, was primarily due to net unfavorable foreign currency exchange rates during the third quarter of fiscal 2012.

The decrease in interest and other income (expense), net, during the nine months ended December 31, 2011, as compared to the nine months ended December 31, 2010, was primarily due to (a) net unfavorable foreign currency exchange rates during the second and third quarters of fiscal 2012 and (b) equity in net loss of an unconsolidated affiliate. The decrease was partially offset by (a) favorable foreign currency exchange rates during the first quarter of fiscal 2012 and (b) grant income awarded to set up AVRL during the second quarter of fiscal 2012.

Income Tax Provision

The following sets forth our income tax provision for the periods indicated (in thousands, except percentages):

	Three Months Ended December 31,		Nine Months Ended December 31,	
	2011	2010	2011	2010
Income tax provision	\$1,696	\$2,045	\$4,892	\$6,711
Effective tax rate	37	% 35	% 37	% 38

Three and Nine Months Ended December 31, 2011 Compared to Three and Nine Months Ended December 31, 2010

During the three months ended December 31, 2011 and 2010, our income tax provision was \$1.7 million, based on an effective tax rate of 37%, and \$2.0 million, based on an effective tax rate of 35%, respectively. The increase in the effective tax rate during the three months ended December 31, 2011, as compared to the three months ended December 31, 2010, was primarily due to tax benefits resulting from the retroactive extension of the federal research and development tax credit during the three months ended December 31, 2010, partially offset by an expense recognized during the three months ended December 31, 2010 as a result of a decrease in California deferred tax assets due to a change in tax law impacting California apportionment.

During the nine months ended December 31, 2011 and 2010, our income tax provision was \$4.9 million, based on an effective tax rate of 37%, and \$6.7 million, based on an effective tax rate of 38%, respectively. The decrease in the effective tax rate during the nine months ended December 31, 2011, as compared to the nine months ended December 31, 2010, was primarily due to lower state tax expenses resulting from the change in California to a single factor apportionment.

We did not have any unrecognized tax benefits as of December 31, 2011 or December 31, 2010. During the three and nine months ended December 31, 2011 and 2010, we did not recognize any interest or penalties related to unrecognized tax benefits.

LIQUIDITY AND CAPITAL RESOURCES

Total cash, cash equivalents and short-term and long-term investments at December 31, 2011 and March 31, 2011 were as follows (in thousands, except percentages):

December 31, 2011	March 31, 2011
----------------------	-------------------

Edgar Filing: ABAXIS INC - Form 10-Q

Cash and cash equivalents	\$ 35,368	\$43,471		
Short-term investments	22,366	25,981		
Long-term investments	30,189	36,237		
Total cash, cash equivalents and investments	\$ 87,923	\$105,689		
Percentage of total assets	51	%	56	%

Cash Flow Changes

Cash provided by (used in) the nine months ended December 31, 2011 and 2010 were as follows (in thousands):

	Nine Months Ended December 31,	
	2011	2010
Net cash provided by operating activities	\$17,339	\$10,684
Net cash provided by investing activities	2,935	3,755
Net cash (used in) provided by financing activities	(28,060)	1,192
Effect of exchange rate changes on cash and cash equivalents	(317)	68
Net (decrease) increase in cash and cash equivalents	\$(8,103)	\$15,699

Table of Contents

At December 31, 2011, we had net working capital of \$96.1 million compared to \$107.5 million at March 31, 2011. Cash and cash equivalents at December 31, 2011 were \$35.4 million compared to \$43.5 million at March 31, 2011. The decrease in cash and cash equivalents during the nine months ended December 31, 2011 was primarily due to purchases of investments of \$26.4 million, purchases of property and equipment of \$6.0 million, payments made for tax withholdings related to net share settlements of restricted stock units of \$2.2 million and repurchases of common stock of \$27.3 million, partially offset by net cash provided by operating activities of \$17.3 million and proceeds from maturities and redemptions of investments of \$35.3 million.

Operating Activities

During the nine months ended December 31, 2011, we generated \$17.3 million in cash from operating activities, compared to \$10.7 million during the nine months ended December 31, 2010. The cash provided by operating activities during the nine months ended December 31, 2011 was primarily the result of net income of \$8.4 million, adjusted for the effects of non-cash adjustments including depreciation and amortization of \$3.7 million and share-based compensation expense of \$4.2 million, partially offset by a decrease of \$717,000 related to excess tax benefits from share-based awards.

Other changes in operating activities during the nine months ended December 31, 2011 were as follows:

(i) Receivables, net decreased by \$1.9 million, from \$27.9 million at March 31, 2011 to \$26.0 million as of December 31, 2011, primarily due to higher sales in the last month of the quarter ended March 31, 2011.

(ii) Prepaid expenses and other current assets increased by \$2.1 million, from \$3.5 million at March 31, 2011 to \$5.6 million as of December 31, 2011, primarily due to the timing of prepaid expenses during the quarter ended December 31, 2011.

(iii) Accrued taxes decreased by \$559,000, from \$559,000 at March 31, 2011 to \$0 as of December 31, 2011, primarily due to the timing of income tax payments during the quarter ended December 31, 2011.

(iv) Total deferred revenue increased by \$733,000, resulting from an increase in the current portion of deferred revenue of \$185,000, from \$953,000 at March 31, 2011 to \$1.1 million as of December 31, 2011, and an increase in the non-current portion of deferred revenue of \$548,000 from \$1.7 million at March 31, 2011 to \$2.3 million as of December 31, 2011. The increase in balances are due to an increase in maintenance contracts offered to customers from time to time in the form of free goods in connection with the sale of our products and the relative selling price method of maintenance contracts, partially offset by deferred revenue recognized ratably over the life of the maintenance contract.

(v) Total warranty reserves increased by \$383,000, resulting from an increase in the current portion of warranty reserves of \$92,000, from \$1.0 million at March 31, 2011 to \$1.1 million as of December 31, 2011, and an increase in the non-current portion of warranty reserves of \$291,000, from \$191,000 at March 31, 2011 to \$482,000 as of December 31, 2011. The increase in warranty reserves is primarily based on (a) the number of instruments in standard warranty, estimated product failure rates and estimated repair costs and (b) an estimate of defective reagent discs and replacement costs. Management continually evaluates the sufficiency of the warranty provisions and makes adjustments when necessary. If an unusual performance rate related to warranty claims is noted, an additional warranty accrual may be assessed and recorded when a failure event is probable and the cost can be reasonably estimated.

We anticipate that we will incur incremental additional costs to support our future operations, including further additional pre-clinical testing and clinical trials for our current and future products; research and design costs related

to the continuing development of our current and future products; acquisition of capital equipment for our manufacturing facility and costs to develop and operate AVRL, our full service laboratory testing facility for veterinarians across the United States. Furthermore, during the three and nine months ended December 31, 2011, we incurred legal costs related to (a) a patent infringement lawsuit against Cepheid with respect to Cepheid's Methicillin-resistant Staphylococcus aureus (MRSA) product, on which Cepheid has ceased paying license royalties, and (b) compliance in an investigation by the United States Federal Trade Commission of a competitor. In the future, we may continue to incur additional legal costs.

Investing Activities

Net cash provided by investing activities during the nine months ended December 31, 2011 totaled \$2.9 million, compared to net cash provided by investing activities of \$3.8 million during the nine months ended December 31, 2010. Changes in investing activities were as follows:

Investments. Cash provided by proceeds from maturities and redemptions of investments in certificates of deposits, commercial paper, corporate bonds, municipal bonds and U.S. agency securities totaled \$35.3 million during the nine months ended December 31, 2011. Cash used to purchase investments in certificates of deposits, corporate bonds, municipal bonds and U.S. agency securities totaled \$26.4 million during the nine months ended December 31, 2011.

Property and Equipment. Cash used to purchase property and equipment totaled \$6.0 million during the nine months ended December 31, 2011, primarily to support (a) increased capacity requirements in our production line, (b) leasehold improvements on our principal facilities and (c) development of a full-service laboratory testing facility for AVRL in Olathe, Kansas. We anticipate that we will continue to purchase property and equipment as necessary in the normal course of our business.

Table of Contents

Financing Activities

Net cash used in financing activities during the nine months ended December 31, 2011 totaled \$28.1 million, primarily due to payments made for tax withholdings related to net share settlements of restricted stock units of \$2.2 million and repurchases of common stock of \$27.3 million, partially offset by proceeds from the exercise of stock options of \$576,000 and excess tax benefits from share-based awards of \$717,000.

Share Repurchases

In August 2011, the Board of Directors authorized the repurchase of up to an aggregate of \$40.0 million of our common stock. As of December 31, 2011, \$12.7 million of shares repurchases may yet be purchased under such authorization. In January 2012, the Board of Directors approved a \$15.0 million increase to its existing share repurchase program, to a total of \$55.0 million. The repurchases are made from time to time on the open market at prevailing market prices or in negotiated transactions off the market. Repurchased shares are retired.

During the nine months ended December 31, 2011, we repurchased 1,168,000 shares for \$27.3 million, including commissions, at an average per share cost of \$23.41.

Contractual Obligations

Purchase Commitments. In October 2008, we entered into an OEM agreement with Scandinavian Micro Biodevices APS (“SMB”) of Denmark to purchase coagulation and specialty analyzers and related cartridges. Effective January 2011, we amended and restated our OEM agreement, including the terms of our minimum purchase commitments. Under the amended agreement, we committed to purchase a minimum number of coagulation and specialty analyzers and related cartridges on an annual basis during each calendar year 2011 through 2015. Our purchase obligations in the future may be adjusted if our minimum purchase commitments are not met during a calendar year period. At December 31, 2011, our total remaining outstanding commitment due is approximately \$11.5 million.

In December 2011, we executed a term sheet to enter into a development and supply equipment agreement with Diatron MI PLC (“Diatron”) of Hungary to purchase Diatron hematology instruments. Under the terms of this agreement, we committed to purchase a minimum number of hematology instruments on an annual basis during each calendar year 2012 through 2014, which can be amended upon agreement by both parties. At December 31, 2011, our outstanding commitment due is approximately \$12.6 million. The commitment amount is based on the minimum number of hematology instruments that we are required to purchase, the cost of the instruments and the Euro exchange rate at period-end. Since the exchange rate can fluctuate in the future, the commitment in absolute dollars will change accordingly.

Patent Licensing Agreement. Effective January 2009, we entered into a license agreement with Inverness Medical Switzerland GmbH, now known as Alere Switzerland GmbH (“Alere”). Under our license agreement, we licensed co-exclusively certain worldwide patent rights related to lateral flow immunoassay technology in the field of animal health diagnostics in the professional marketplace. The license agreement provides that Alere shall not grant any future rights to any third parties under its current lateral flow patent rights in the animal health diagnostics field in the professional marketplace. The license agreement enables us to develop and market products under rights from Alere to address animal health and laboratory animal research markets.

In exchange for the license rights, we (i) paid an up-front license fee of \$5.0 million to Alere in January 2009, (ii) agreed to pay royalties during the term of the agreement, based solely on sales of products in a jurisdiction country covered by valid and unexpired claims in that jurisdiction under the licensed Alere patent rights, and (iii) agreed to

pay a yearly minimum license fee of between \$500,000 to \$1.0 million per year, which fee will be creditable against any royalties due during such calendar year. The royalties, if any, are payable through the date of the expiration of the last valid patent licensed under the agreement that includes at least one claim in a jurisdiction covering products we sell in that jurisdiction. The yearly minimum fees became payable starting in fiscal 2011 for so long as we desire to maintain exclusivity under the agreement.

Notes Payable. Effective January 2011, we have a ten year loan agreement with the Community Redevelopment Agency of the City of Union City (“the Agency”) whereby the Agency provides us with an unsecured loan of up to \$1.0 million, primarily to purchase capital equipment. The loan bears interest at 5.0% and is payable quarterly. As of December 31, 2011, our short-term and long-term notes payable balances were \$100,000 and \$808,000, respectively, and we recorded the short-term balance in other accrued liabilities on the condensed consolidated balance sheets. The entire outstanding balance of the note shall be payable in full on the earlier of: (i) December 2020, or (ii) the date Abaxis ceases operations in Union City, California. The Agency also has the right to accelerate the maturity date and declare all balances immediately due and payable upon the event of default as defined in the loan agreement. We evaluate covenants in our loan agreement on a quarterly basis, and we were in compliance with such covenants as of December 31, 2011.

In accordance with the terms of the loan agreement, the Agency will provide Abaxis with an annual credit that can be applied against the accrued interest and outstanding principal balance on a quarterly basis. The Agency determines the annual credit based on certain taxes paid by Abaxis to the City of Union City, California for a specified period, as defined in the loan agreement. We anticipate that our annual credits from the Agency will be used to fully repay our notes payable due to the Agency. We may carry forward unused quarterly credits to apply against our outstanding balance in a future period. Credits applied to repay our notes payable and accrued interest are recorded in “Interest and other income (expense), net” on the condensed consolidated statements of income.

Table of Contents

Contingencies

On June 28, 2010, we filed a patent infringement lawsuit against Cepheid with respect to Cepheid's Methicillin-resistant Staphylococcus aureus (MRSA) product, on which Cepheid has ceased paying license royalties. On December 17, 2010, Cepheid filed its amended answer and certain counterclaims seeking findings of no breach of contract, non-infringement, unenforceability and invalidity of the asserted patents, and a declaration regarding the patent term of one of the patents. We believe the counterclaims raised by Cepheid are without merit and intend to contest them vigorously. Because of the cost involved in pursuing patent infringement cases, we believe the cost of this litigation could have a material adverse effect on Abaxis, our consolidated financial position and results of operations. As of December 31, 2011, we had not recorded future litigation and related expenses to pursuing the patent infringement case and an estimate of such costs cannot be made at this time. A claims construction hearing was held in June 2011 and the court has issued its claims construction order. The case is ongoing. A trial date has been set for September 24, 2012.

We are involved from time to time in various litigation matters in the normal course of business. Other than as described above, we believe that the ultimate resolution of these matters will not have a material effect on our consolidated financial position or results of operations. There can be no assurance that existing or future legal proceedings arising in the ordinary course of business or otherwise will not have a material adverse effect on our business, consolidated financial position, results of operations or cash flows.

Off-Balance Sheet Arrangements

As of December 31, 2011, we did not have any off-balance sheet arrangements, as defined in Item 303 of Regulation S-K promulgated under the Securities Act of 1933. In addition, we identified no variable interests in any variable interest entities.

Financial Condition

We anticipate that our existing capital resources and anticipated revenues from the sales of our products and services will be adequate to satisfy our currently planned operating and financial requirements through at least the next 12 months. Our future capital requirements will largely depend upon the increased market acceptance of our point-of-care blood analyzer products and of Abaxis Veterinary Reference Laboratories. However, our sales for any future periods are not predictable with a significant degree of certainty. Regardless, we may seek to raise additional funds to pursue strategic opportunities.

RECENT ACCOUNTING PRONOUNCEMENTS

A discussion of recent accounting pronouncements is included in Note 2 of the Notes to Condensed Consolidated Financial Statements contained in this Quarterly Report on Form 10-Q.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Interest Rate Risk

We are exposed to the impact of interest rate changes with respect to our short-term and long-term investments. Our investment objective is to invest excess cash in cash equivalents and in various types of investments to maximize yields without significantly increased risk. At December 31, 2011, our short-term investments totaled \$22.4 million, consisting of certificates of deposits, corporate bonds and municipal bonds and our long-term investments totaled \$30.2 million, consisting of certificates of deposits, corporate bonds, municipal bonds and U.S. agency securities.

As of December 31, 2011, we had \$44.3 million in investments classified as held-to-maturity and carried at amortized cost. We have the ability to hold the investments classified as held-to-maturity in our investment portfolio at December 31, 2011 until maturity and therefore, we believe we have no material exposure to interest rate risk. As of December 31, 2011, our investments classified as available-for-sale totaled \$8.3 million, which we recorded at fair market value with unrealized gains or losses resulting from changes in fair value reported as a separate component of accumulated other comprehensive income (loss), net of any tax effects, in stockholders' equity. A sensitivity analysis assuming a hypothetical 10% movement in interest rates applied to our total investment balances at December 31, 2011 indicated that such market movement would not have a material effect on our business, operating results or financial condition. We have not experienced any significant loss on our investment portfolio during fiscal 2011 or during the nine months ended December 31, 2011.

As a matter of management policy, we do not currently enter into transactions involving derivative financial instruments. In the event we do enter into such transactions in the future, such items will be accounted for in accordance with Accounting Standards Codification 815, "Derivatives and Hedging."

Table of Contents

Investment in a Privately Held Company

In February 2011, we purchased a 15% equity ownership interest in Scandinavian Micro Biodevices APS (“SMB”), a privately-held developer and manufacturer of point-of-care diagnostic products for veterinary use, for \$2.8 million in cash. SMB, based in Farum, Denmark, has been the original equipment manufacturer of our VetScan VSpro point-of-care coagulation and specialty analyzer since 2008. The investment is recorded in “Investment in Unconsolidated Affiliate” in our condensed consolidated balance sheets and we use the equity method to account for our investment in this entity that we do not control, but where we have the ability to exercise significant influence. As of December 31, 2011, the total carrying amount of our investment in SMB was \$2.7 million. The investment is inherently risky and we could lose our entire investment in this company. We have not recorded an impairment charge on this investment as of December 31, 2011 or during the nine months ended December 31, 2011.

Foreign Currency Rate Fluctuations

We operate primarily in the United States and a majority of our revenues, cost of revenues, operating expenses and capital purchasing activities are transacted in U.S. dollars. However, we are exposed to foreign currency exchange rate fluctuations on the hematology products purchased from Diatron MI PLC, which are primarily denominated in Euros.

Abaxis Europe GmbH, our wholly-owned subsidiary since July 2008, markets, promotes and distributes diagnostic systems for medical and veterinary uses. Abaxis Europe GmbH’s functional currency is in U.S. dollars. Foreign currency denominated account balances of our subsidiary are remeasured into U.S. dollars at the end-of-period exchange rates for monetary assets and liabilities, and historical exchange rates for nonmonetary assets. Accordingly, the effects of foreign currency transactions, and of remeasuring the financial condition into the functional currency, resulted in foreign currency gains and losses, which were included in “Interest and other income (expense), net” on our consolidated statements of income. For our sales denominated in foreign currencies, we are exposed to foreign currency exchange rate fluctuations on revenue and collection of receivables. To the extent the U.S. dollar strengthens against the Euro currency, the translation of the foreign currency denominated transactions may result in reduced cost of revenues and operating expenses. Similarly, our cost of revenues and operating expenses will increase if the U.S. dollar weakens against the Euro currency.

Other than the foregoing, there have been no material changes in our market risk during the three months ended December 31, 2011 compared to the disclosures in Part II, Item 7A of our Annual Report on Form 10-K for the fiscal year ended March 31, 2011.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

The Company’s management, with the participation of the Company’s principal executive officer and principal financial officer, has evaluated that the effectiveness of the Company’s disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, (the “Exchange Act”), as of the end of the period covered by this report. Based on such evaluation, the Company’s principal executive officer and principal financial officer, have concluded that, as of the end of such period, the Company’s disclosure controls and procedures were effective.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting during the fiscal quarter ended December 31, 2011 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting, as defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act.

Inherent Limitations on Controls and Procedures

A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risks that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. Accordingly, even an effective system of internal control will provide only reasonable assurance that the objectives of the internal control system are met.

ItemControls and Procedures

4T.

Not applicable.

Table of Contents

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

On June 28, 2010, we filed a patent infringement lawsuit against Cepheid with respect to Cepheid's Methicillin-resistant Staphylococcus aureus (MRSA) product, on which Cepheid has ceased paying license royalties. On December 17, 2010, Cepheid filed its amended answer and certain counterclaims seeking findings of no breach of contract, non-infringement, unenforceability and invalidity of the asserted patents, and a declaration regarding the patent term of one of the patents. We believe the counterclaims raised by Cepheid are without merit and intend to contest them vigorously. Because of the cost involved in pursuing patent infringement cases, we believe the cost of this litigation could have a material adverse effect on Abaxis, our consolidated financial position and results of operations. As of December 31, 2011, we had not recorded future litigation and related expenses to pursuing the patent infringement case and an estimate of such costs cannot be made at this time. A claims construction hearing was held in June 2011 and the court has issued its claims construction order. The case is ongoing. A trial date has been set for September 24, 2012.

We are involved from time to time in various litigation matters in the normal course of business. Other than as described above, we believe that the ultimate resolution of these matters will not have a material effect on our consolidated financial position or results of operations. There can be no assurance that existing or future legal proceedings arising in the ordinary course of business or otherwise will not have a material adverse effect on our business, consolidated financial position, results of operations or cash flows.

Item 1A. Risk Factors

RISK FACTORS THAT MAY AFFECT OUR PERFORMANCE

Our future performance is subject to a number of risks. If any of the following risks actually occur, our business could be harmed and the trading price of our common stock could decline.

When used in these risk factors, the words "anticipates," "believes," "continue," "could," "estimates," "expects," "future," "intends," "may," "might," "plans," "projects," "will" and similar expressions identify forward-looking statements. Our actual results could differ materially from those that we project in the forward-looking statements as a result of factors that we have set forth throughout this document as well as additional risks not presently known to us or that we currently believe are immaterial that may also significantly impair our business operations.

In evaluating our business, you should carefully consider the following risks in addition to the other information in our Annual Report on Form 10-K for the fiscal year ended March 31, 2011 as filed with the Securities and Exchange Commission on June 13, 2011. We note these factors for investors as permitted by the Private Securities Litigation Reform Act of 1995. It is not possible to predict or identify all such factors and, therefore, you should not consider the following risks to be a complete statement of all the potential risks or uncertainties that we face.

Our facilities and manufacturing operations are vulnerable to interruption as a result of natural disasters and system failures. Any such interruption may harm our business.

Our success depends on the efficient and uninterrupted operation of our manufacturing operations, which are co-located with our corporate headquarters in Union City, California. These manufacturing operations are vulnerable to damage or interruption from earthquakes, fire, floods, power loss, telecommunications failures, break-ins and similar events. A failure of manufacturing operations, be it in the development and manufacturing of our Piccolo or VetScan blood chemistry analyzers or the reagent discs used in the blood chemistry analyzers, could result in our

inability to supply customer demand. We do not have a backup facility to provide redundant manufacturing capacity in the event of a system failure or other significant loss or problem. Accordingly, if our manufacturing operations in Union City, California were interrupted, we may be required to bring an alternative facility online, a process that could take several weeks to several months or more.

Additionally, we rely on several information systems to keep financial records, process customer orders, manage inventory, process shipments to customers and operate other critical functions. If we were to experience a system disruption in the information technology systems that enable us to interact with customers and suppliers, it could result in the loss of sales and customers and significant incremental costs, which could adversely affect our business.

Although we carry property and business interruption insurance, our coverage may not be adequate to compensate us for all losses that may occur.

Table of Contents

We are not able to predict sales in future quarters and a number of factors affect our periodic results, which makes our quarterly operating results less predictable.

We are not able to accurately predict our sales in future quarters. Our revenue in the medical and veterinary markets is derived primarily by selling to distributors who resell our products to the ultimate user. While we are better able to predict sales of our reagent discs, as we sell these discs primarily for use with blood chemistry analyzers that we sold in prior periods, we generally are unable to predict with much certainty sales of our blood chemistry analyzers, as we typically sell our blood chemistry analyzers to new users. Accordingly, our sales in any one quarter or period are not indicative of our sales in any future period.

We generally operate with a limited order backlog, because we ship our products shortly after we receive the orders from our customers. As a result, our product sales in any quarter are generally dependent on orders that we receive and ship in that quarter. As a result, any such revenue shortfall would immediately materially and adversely impact our operating results and financial condition.

The sales cycle for our products can fluctuate, which may cause revenue and operating results to vary significantly from period to period. We believe this fluctuation is primarily due (i) to seasonal patterns in the decision making processes by our independent distributors and direct customers, (ii) to inventory or timing considerations by our distributors and (iii) on the purchasing requirements of the U.S. government to acquire our products. Accordingly, we believe that period to period comparisons of our results of operations are not necessarily meaningful.

In the future, our periodic operating results may vary significantly depending on, but not limited to, a number of factors, including:

- new product announcements made by us or our competitors;
- changes in our pricing structures or the pricing structures of our competitors;
- our ability to develop, introduce and market new products or services on a timely basis, or at all;
- our manufacturing capacities and our ability to increase the scale of these capacities;
- the mix of product sales between our instruments and our consumable products;
- the amount we spend on research and development; and
- changes in our strategy.

We depend on limited or sole suppliers, many of whom we do not have long-term contracts with, and failure of our suppliers to provide the components or products to us could harm our business.

We use several key components that are currently available from limited or sole sources as discussed below.

- **Blood Chemistry Analyzer Components:** Our blood analyzer products use several technologically-advanced components that we currently purchase from a limited number of suppliers, including certain components from single source suppliers, Hamamatsu Corporation and UDT Sensors (a division of OSI Optoelectronics). Our analyzers also use a printer that is primarily made by Seiko North America Corporation. The loss of the supply of any of these components could force us to redesign our blood chemistry analyzers.

- **Reagent Discs:** Two injection-molding manufacturers, C. Brewer & Co. and Nipro, Inc., currently make the molded plastic discs that, when loaded with reagents and welded together, form our reagent disc products. We believe that only a few manufacturers are capable of producing these discs to the narrow tolerances that we require. To date, we have only qualified these two manufacturers to manufacture the molded plastic discs.
- **Reagent Chemicals:** We currently depend on the following single source vendors for some of the chemicals that we use to produce the dry reagent chemistry beads that are either inserted in our reagent discs or sold as stand-alone products: Amano Enzyme USA Co., Ltd., Sekisui Diagnostics (formerly Genzyme Diagnostics), Kikkoman Corporation Biochemical Division, Microgenics Corporation, a division of Thermo Fisher Scientific, Roche Molecular Biochemicals of Roche Diagnostics Corporation, a division of F. Hoffmann-La Roche, Ltd., SA Scientific Co., Sigma Aldrich Inc. and Toyobo Specialties.

We market original equipment manufacturer supplied products that are currently available from limited sources as discussed below.

- **Hematology Instruments and Reagent Kits:** Our VetScan hematology instruments are manufactured by Diatron in Hungary and are purchased by us as a completed instrument. In addition, currently, we have qualified two suppliers to produce the reagent kits for our hematology instruments: Clinical Diagnostic Solutions, Inc. and Diatron.
- **Coagulation and Specialty Analyzers and Cartridges:** Our VetScan VSpro coagulation and specialty analyzers and cartridges are manufactured by Scandinavian MicroBiodevices APS in Denmark and are purchased by us as completed products.
- **i-STAT Analyzers and Cartridges:** Our VetScan i-STAT 1 analyzers and cartridges are manufactured by Abbott Point of Care Inc. in North America and are purchased by us as completed products.

Table of Contents

We primarily operate on a purchase order basis with most of our suppliers and, therefore, these suppliers are under no contractual obligation to supply us with their products or to do so at specified prices. Although we believe that there may be potential alternate suppliers available for these critical components, to date we have not qualified additional vendors beyond those referenced above and cannot assure you we would be able to enter into arrangements with additional vendors on favorable terms, or at all. For the suppliers of original equipment manufactured products that we have long-term contracts with, there can be no assurance that these suppliers will always fulfill their obligations under these contracts, or that any suppliers will not experience disruptions in their ability to supply our requirements for products. In addition, under some contracts with suppliers we have minimum purchase obligations and our failure to satisfy those obligations may result in loss of some or all of our rights under these contracts.

Because we are dependent on a limited number of suppliers and manufacturers for our products, we are particularly susceptible to any interruption in the supply of these products or the viability of our assembly arrangements. The loss of any one of these suppliers or a disruption in our manufacturing arrangements could adversely affect our business and financial condition.

We would fail to achieve anticipated revenue if the market does not accept our products and services.

We believe that our core compact blood chemistry analyzer product differs substantially from current blood chemistry analyzers on the market. We compete with centralized laboratories that offer a greater number of tests than our products, but do so at a greater overall cost and require more time. We also compete with other point-of-care analyzers that cost more, require more maintenance and offer a narrower range of tests. However, these point-of-care analyzers are generally marketed by larger companies which have greater resources for sales and marketing, in addition to a recognized brand name and established distribution relationships.

In the human medical market, we believe that our blood chemistry analyzers offer customers many advantages, including substantial improvements in practice efficiencies. However, the implementation of point-of-care diagnostics in physicians' offices involves changes to current standard practices, such as using large clinical laboratories, and adopting our technology requires a shift in both the procedures and mindset of care providers. The human medical market in particular is highly regulated, structured, difficult to penetrate and often slow to adopt new product offerings. If we are unable to convince large numbers of medical clinics, hospitals and other point-of-care environments of the benefits of our Piccolo blood chemistry analyzers and our other products, we will suffer lost sales and could fail to achieve anticipated revenue.

Historically, in the veterinary market, we have marketed our VetScan systems through both direct sales and distribution channels to veterinarians. We continue to develop new animal blood tests to expand our product offerings and we cannot be assured that these tests will be accepted by the veterinary market. Any failure to achieve market acceptance with our current or future products would harm our business and financial condition.

In fiscal 2011, we began developing a full-service laboratory testing facility, Abaxis Veterinary Reference Laboratories ("AVRL"), based in Olathe, Kansas. In October 2011, AVRL began providing veterinary reference laboratory diagnostic and consulting services for veterinarians in the United States. AVRL also focuses on providing specialty and esoteric testing and analysis. We cannot be assured that AVRL or its services will be accepted by the veterinary market. If we are unable to convince large numbers of veterinarians of the benefits of AVRL or otherwise fail to achieve market acceptance, our growth will be limited accordingly, which could harm our laboratory business and financial condition.

We rely on patents and other proprietary information, the loss of which would negatively affect our business.

As of December 31, 2011, 56 patent applications have been filed on our behalf with the United States Patent and Trademark Office (“USPTO”), of which 32 patents have been issued and 25 patents are currently active. Additionally, we have filed several international patent applications covering the same subject matter as our domestic applications. The patent position of any medical device manufacturer, including us, is uncertain and may involve complex legal and factual issues. Consequently, we may not be issued any additional patents, either domestically or internationally. Furthermore, our patents may not provide significant proprietary protection because there is a chance that they will be circumvented or invalidated. We cannot be certain that we were the first creator of the inventions covered by our issued patents or pending patent applications, or that we were the first to file patent applications for these inventions, because (1) the USPTO maintains all patent applications that are not filed in any foreign jurisdictions in secrecy until it issues the patents (when a patent application owner files a request for nonpublication) and (2) publications of discoveries in the scientific or patent literature tend to lag behind actual discoveries by several months. We may have to participate in interference proceedings, which are proceedings in front of the USPTO, to determine who will be issued a patent. These proceedings could be costly and could be decided against us.

We also rely upon copyrights, trademarks and unpatented trade secrets. Others may independently develop substantially equivalent proprietary information and techniques that would undermine our proprietary technologies. Further, others may gain access to our trade secrets or disclose such technology. Although we require our employees, consultants and advisors to execute agreements that require that our corporate information be kept confidential and that any inventions by these individuals are property of Abaxis, there can be no assurance that these agreements will provide meaningful protection or adequate remedies for our trade secrets in the event of unauthorized use or disclosure of such information. The unauthorized dissemination of our confidential information would negatively impact our business.

Table of Contents

On June 28, 2010, we filed a patent infringement lawsuit against Cepheid with respect to Cepheid's Methicillin-resistant Staphylococcus aureus (MRSA) product, on which Cepheid has ceased paying license royalties. On December 17, 2010, Cepheid filed its amended answer and certain counterclaims seeking findings of no breach of contract, non-infringement, unenforceability and invalidity of the asserted patents, and a declaration regarding the patent term of one of the patents. We believe the counterclaims raised by Cepheid are without merit and intend to contest them vigorously. Patent infringement lawsuits are expensive and time-consuming. We believe the cost of this litigation could have a material adverse effect on our business, our consolidated financial position and results of operations. As of December 31, 2011, we have not recorded future litigation and related expenses to pursuing the patent infringement case and an estimate of such costs cannot be made at this time.

We must increase sales of our Piccolo and VetScan products or we may not be able to increase or sustain profitability.

Our ability to continue to be profitable and to increase profitability will depend, in part, on our ability to increase our sales volumes of our Piccolo and VetScan products. Increasing the sales volume of our products will depend upon, among other things, our ability to:

- continue to improve our existing products and develop new and innovative products;
- increase our sales and marketing activities;
- effectively manage our manufacturing activities; and
- effectively compete against current and future competitors.

We cannot assure you that we will be able to successfully increase our sales volumes of our products to increase or sustain profitability.

We must continue to increase our sales, marketing and distribution efforts in the human diagnostic market or our business will not grow.

The human diagnostic market is fragmented, heavily regulated and constantly changing. Our limited sales, marketing and distribution capabilities are continually challenged to translate these changes into compelling value propositions for our prospective customers. Accordingly, we cannot assure you that:

- we will be able to maintain consistent growth through our key distributors in the human diagnostic market;
- the costs associated with sales, marketing and distributing our products will not be excessive; or
- government regulations or private insurer policies will not adversely affect our ability to be successful.

Should we fail to effectively develop our sales, marketing and distribution efforts and navigate regulatory challenges, our growth will be limited and our results of operations will be adversely affected.

We depend on key members of our management and scientific staff and, if we fail to retain and recruit qualified individuals, our ability to execute our business strategy and generate sales would be harmed.

We are highly dependent on the principal members of our management and scientific staff. The loss of any of these key personnel, including in particular Clinton H. Severson, our President, Chief Executive Officer and Chairman of our Board of Directors, might impede the achievement of our business objectives. We may not be able to continue to

attract and retain skilled and experienced marketing, sales and manufacturing personnel on acceptable terms in the future because numerous medical products and other high technology companies compete for the services of these qualified individuals. We currently do not maintain key man life insurance on any of our employees.

We rely primarily on distributors to sell our products and we rely on sole distributor arrangements in a number of countries. Our failure to successfully develop and maintain these relationships could adversely affect our business.

We sell our medical and veterinary products primarily through a limited number of distributors. As a result, we are dependent upon these distributors to sell our products and to assist us in promoting and creating a demand for our products. We operate on a purchase order basis with the distributors and the distributors are under no contractual obligation to continue carrying our products. Further, many of our distributors may carry our competitors' products, and may promote our competitors' products over our own products.

We depend on a number of distributors in North America who distribute our VetScan products. We depend on our distributors to assist us in promoting our products in the veterinary market, and accordingly, if one or more of our distributors were to stop selling our products in the future, we may experience a temporary sharp decline or delay in our sales revenue until our customers identify another distributor or purchase products directly from us.

Table of Contents

In the United States medical market, we depend on a few distributors for our Piccolo products. We entered into formal distribution agreements with the following distributors to sell and market Piccolo chemistry analyzers and medical reagent discs: Cardinal Health, Henry Schein's Medical Group, McKesson Medical-Surgical Inc. and PSS World Medical, Inc. We depend on these distributors to assist us in promoting market acceptance of our Piccolo chemistry analyzers. The loss of any of these distributors would have a material negative impact on our operating results and financial condition.

Internationally, we rely on only a few distributors for our products in both the medical and veterinary diagnostic markets. We currently rely on distributors that carry either our medical or veterinary products in the following countries: Afghanistan, Australia, Austria, Belgium, Canada, Czech Republic, Denmark, France, Germany, Hong Kong, India, Ireland, Israel, Italy, Japan, Korea, Macao, the Netherlands, New Zealand, the Philippines, Portugal, Romania, Russia, Singapore, South Africa, Spain, Sweden, Switzerland, Turkey, the United Arab Emirates, the United Kingdom and the United States. Our distributors in each of these countries are responsible for obtaining the necessary approvals to sell our new and existing products. These distributors may not be successful in obtaining proper approvals for our new and existing products in their respective countries, and they may not be successful in marketing our products. Furthermore, an inability of, or any delays by, our distributor in receiving the necessary approvals for our new or other products can adversely impact our revenues in a country. We plan to continue to enter into additional distributor relationships to expand our international distribution base and presence. However, we may not be successful in entering into additional distributor relationships on favorable terms, or at all. In addition, our distributors may terminate their relationship with us at any time. Historically, we have experienced a high degree of turnover among our international distributors. This turnover makes it difficult for us to establish a steady distribution network overseas. Consequently, we may not be successful in marketing our Piccolo and VetScan products internationally, and our business and financial condition may be harmed as a result.

We need to successfully manufacture and market additional reagent discs for the human diagnostic market if we are to compete in that market.

We have developed a blood analysis system that consists of a portable blood analyzer and single-use reagent discs. Each reagent disc performs a series of standard blood tests. We believe that it is necessary to develop additional series of reagent discs with various tests for use with the Piccolo and VetScan chemistry analyzers. Historically, we have developed reagent discs suitable for the human medical and veterinary diagnostic markets. We have received 510(k) clearances from the U.S. Food and Drug Administration ("FDA") for 26 test methods in the human medical market. These tests are included in standard tests for which the medical community receives reimbursements from third-party payors such as managed care organizations and Medicare. We may not be able to successfully manufacture or market these reagent discs. Our failure to meet these challenges will materially adversely affect our operating results and financial condition.

We rely on relationships with partners and other third parties that license our technologies and pay us royalties on sales of their products. Failure to maintain these relationships, poor performance by these companies or disputes with these companies could negatively impact our business.

We rely on collaborative relationships with other companies for revenues resulting from royalties payable by these third parties in connection with technologies that they license from us. For example, we entered into a license agreement with Cepheid in fiscal 2006 to license a portion of our patent portfolio covering lyophilization technology. Under the agreement, Cepheid paid us royalties based on sales of Cepheid products using the licensed technology. On October 1, 2010, we terminated the entire license as to all or any of Cepheid products due to Cepheid's discontinuation of license royalty payments. As a result of this license termination, we expect that our development and licensing revenue will be adversely and materially impacted. If other third parties fail to perform under license agreement or generate royalties to the level of our expectations, our operating results may be harmed. In

addition, reliance on collaborative relationships poses a number of risks, including the following risks:

- we may not be able to control the amount and timing of resources that our collaborators may devote to products from which we derive royalties;
- disputes may arise with respect to the ownership of rights to technology developed with our partners;
- disagreements with our partners could cause delays in, or termination of, the research, development or commercialization of products or result in litigation or arbitration;
- contracts with our partners may fail to provide significant protection or may fail to be effectively enforced if one of these partners fails to perform;
- should a partner fail to develop or commercialize products based on technologies we may license, we may not receive any future payments or any royalties for the technologies or products;
- collaborative arrangements are often terminated or allowed to expire, such as our former license with Cepheid, which would adversely impact our royalty revenues; and
- our corporate partners may be unable to pay us, particularly in light of current economic conditions.

Given these risks, there is a great deal of uncertainty regarding the success of our current and future collaborative efforts.

Table of Contents

We may not be able to compete effectively with larger, more established entities or their products, or with future organizations or future products, which could cause our sales to decline.

Blood analysis is a well-established field in which there are a number of competitors that have substantially greater financial resources and larger, more established marketing, sales and service organizations than we do. We compete primarily with the following organizations:

- commercial clinical laboratories;
- hospitals' clinical laboratories; and
- manufacturers of bench top multi-test blood analyzers and other testing systems that health care providers can use "on-site" (a listing of our competitors is listed below).

Historically, hospitals and commercial laboratories perform most of the human diagnostic testing, and veterinary specialized commercial laboratories perform most of the veterinary medical testing. We have identified five principal factors that we believe customers typically use to evaluate our products and those of our competitors. These factors include the following:

- range of tests offered;
- immediacy of results;
- cost effectiveness;
- ease of use; and
- reliability of results.

We believe that we compete effectively on each of these factors except for the range of tests offered. Clinical laboratories are effective at processing large panels of tests using skilled technicians and complex equipment. While our current offering of reagent discs cannot provide the same broad range of tests, we believe that in certain markets, our products provide a sufficient breadth of test menus to compete successfully with clinical laboratories given the advantages of our products with respect to the other four factors. In addition, we cannot assure you that we will continue to be able to compete effectively on cost effectiveness, ease of use, immediacy of results or reliability of results. We also cannot assure you that we will ever be able to compete effectively on the basis of range of tests offered.

Our principal competitors in the human diagnostic market are Alere (formerly Inverness Medical Technologies), Alfa Wassermann S.P.A., i-STAT Corporation (which was purchased by Abbott Laboratories), Johnson & Johnson (including its subsidiary, Ortho-Clinical Diagnostics, Inc.), and F. Hoffmann-La Roche Ltd. Many of our competitors in the human diagnostic market have significantly larger product lines to offer and greater financial and other resources than we do. In particular, many of these competitors have large sales forces and well-established distribution channels and brand names. Our principal competitors in the veterinary diagnostic market are Antech, Idexx Laboratories, Inc. and Heska Corporation. Idexx has a larger veterinary product line and sales force than we do and a well-established distribution network and brand name. Consequently, we must develop our distribution channels and significantly expand our direct sales force in order to compete more effectively in these markets.

In fiscal 2011, we began developing a full-service laboratory testing facility, AVRL, based in Olathe, Kansas. Starting in October 2011, AVRL provides veterinary reference laboratory diagnostic and consulting services for veterinarians in the United States. AVRL also focuses on providing specialty and esoteric testing and analysis. Additionally, in January 2011, we formed a strategic alliance with Kansas State University, K-State Veterinary Diagnostic Lab, and a commercial affiliate of Kansas State University, the National Institute for Strategic Technology Acquisition and Commercialization, to enable AVRL to provide a full service commercial laboratory for veterinarians. We will incur significant expenses in connection with this strategic alliance and may incur additional significant expenses in exploring other future opportunities, for which the outcome is uncertain. Pursuing these and other strategic opportunities could distract our management, or divert or expend our limited capital and other resources, which could adversely impact our operating results and financial condition in the future.

Changes in third-party payor reimbursement regulations can negatively affect our business.

By regulating the maximum amount of reimbursement they will provide for blood testing services, third-party payors, such as managed care organizations, pay-per-service insurance plans, Medicare and Medicaid, can indirectly affect the pricing or the relative attractiveness of our human testing products. For example, the Centers for Medicare and Medicaid Services (the “CMS”) set the level of reimbursement of fees for blood testing services for Medicare beneficiaries. If third-party payors decrease the reimbursement amounts for blood testing services, it may decrease the likelihood that physicians and hospitals will adopt point-of-care diagnostics as a viable means of care delivery. Consequently, we would need to charge less for our products. If the government and third-party payors do not provide for adequate coverage and reimbursement levels to allow health care providers to use our products, the demand for our products will decrease and our business and financial condition would be harmed.

Table of Contents

We are subject to numerous governmental regulations and regulatory changes are difficult to predict and may be damaging to our business.

Need for Government Regulation for our Products

Our Piccolo products are medical devices subject to regulation by the FDA, under the Federal Food, Drug, and Cosmetic Act ("FDCA"). Medical devices, to be commercially distributed in the United States, must receive either 510(k) premarket clearance or Premarket Approval ("PMA") from the FDA pursuant to the FDCA prior to marketing. Devices deemed to pose relatively less risk are placed in either class I or II, which generally requires the manufacturer to submit a premarket notification requesting permission for commercial distribution; this is known as 510(k) clearance. Most lower risk, or class I, devices are exempted from this requirement. Devices deemed by the FDA to pose the greatest risk, such as life-sustaining, life supporting or implantable devices, or devices deemed not substantially equivalent to a previously 510(k) cleared device or a preamendment class III device for which PMA applications have not been called, are placed in class III requiring PMA approval. The FDA has classified our Piccolo products as class I or class II devices, depending on their specific intended uses and indications for use.

510(k) Clearance Pathway. To obtain 510(k) clearance, a manufacturer must submit a premarket notification demonstrating that the proposed device is substantially equivalent in intended use, principles of operation, and technological characteristics to a previously 510(k) cleared device or a device that was in commercial distribution before May 28, 1976 for which the FDA has not called for submission of PMA applications. The FDA's 510(k) clearance pathway usually takes from three to six months, but it can take longer.

After a device receives 510(k) clearance, any modification that could significantly affect its safety or effectiveness, or that would constitute a major change in its intended use, requires a new 510(k) clearance or could require a PMA approval. The FDA requires each manufacturer to make this determination in the first instance, but the FDA can review any such decision. If the FDA disagrees with a manufacturer's decision not to seek a new 510(k) clearance, the agency may retroactively require the manufacturer to seek 510(k) clearance or PMA approval. The FDA also can require the manufacturer to cease marketing and/or recall the modified device until 510(k) clearance or PMA approval is obtained, to redesign the device or to submit new data or information to the FDA. Products marketed following the FDA clearance also are subject to significant postmarket requirements.

As of December 31, 2011, we have received the FDA premarket clearance for our Piccolo chemistry analyzer and 26 reagent tests that we have on 15 reagent discs. We are currently developing additional tests which we will have to clear with the FDA through the 510(k) notification procedures. These new test products are crucial for our continued success in the human medical market. If we do not receive 510(k) clearance for a particular product, we will not be able to market that product in the United States until we provide additional information to the FDA and gain premarket clearance. The inability to market a new product during this time could harm our future sales.

Effects of the Clinical Laboratory Improvement Amendments on our Products

Our Piccolo products are also affected by the CLIA. The CLIA are intended to ensure the quality and reliability of all medical testing in the United States regardless of where the tests are performed. The current CLIA regulations divide laboratory tests into the following three categories:

- waived;
- moderately complex; and
- highly complex.

Many of the tests performed using the Piccolo chemistry analyzer are in the “moderately complex” category. This category requires that any location in which testing is performed be certified as a laboratory. Hence, we can only sell some Piccolo products to customers who meet the standards of a laboratory. To receive “laboratory” certification, a testing facility must be certified by the CMS. After the testing facility receives a “laboratory” certification, it must then meet the CLIA regulations. Because we can only sell some Piccolo products to testing facilities that are certified “laboratories,” the market for some products is correspondingly constrained.

We can currently offer the following Piccolo reagent discs as waived tests to the medical market: Basic Metabolic Panel, Comprehensive Metabolic Panel, Electrolyte Panel, General Chemistry 6, General Chemistry 13, Kidney Check, Lipid Panel, Lipid Panel Plus, Liver Panel Plus, MetLyte 8 Panel and Renal Function Panel. Waived status permits untrained personnel to run the Piccolo chemistry analyzer using these tests; thus, extending the sites (doctors’ offices and other point-of-care environments) that can use the Piccolo chemistry analyzer. Although we are engaged in an active program to test and apply for CLIA waivers for additional analytes, we cannot assure you that we will successfully receive CLIA waived status from the FDA for other products. Consequently, for the reagent discs that have not received CLIA waived status, the market for our Piccolo products may be confined to those testing facilities that are certified as “laboratories” and our growth would be limited accordingly, which could harm our business and financial condition.

Table of Contents

Animal and Plant Health Inspection Service Licensure of Veterinary Biologics

Our canine heartworm antigen (“CHW”) diagnostic product is regulated as a veterinary biologic under the Virus, Serum, and Toxin Act of 1913. In October 2009, we announced that we received licensure of our CHW test utilizing a rotor-based assay system consisting of eleven other important canine health determinations from the Animal and Plant Health Inspection Service (“APHIS”). Veterinary biologics are licensed as are their manufacturing facilities. Products are subject to extensive testing to establish their purity, safety, potency, and efficacy. Licensed biologics are also required to be prepared in accordance with a filed Outline of Production, among other requirements. Failure to comply with APHIS licensure or post-marketing approval requirements can result in the inability to obtain product or establishment licenses or cause the revocation or suspension of such licenses.

We are currently developing additional tests that will be subject to APHIS licensure as veterinary biologics. If we do not receive licensure for these additional tests, we will not be able to market those products in the United States and our growth can be limited accordingly.

Need to Comply with Manufacturing Regulations and Various Federal, State, Local and International Regulations

The 1976 Medical Device Amendment also requires us to manufacture our Piccolo products in accordance with Good Manufacturing Practices guidelines. Current Good Manufacturing Practice requirements are set forth in the 21 CFR 820 Quality System Regulation. These requirements regulate the methods used in, and the facilities and controls used for the design, manufacture, packaging, storage, installation and servicing of our medical devices intended for human use. Our manufacturing facility is subject to periodic inspections. In addition, various state regulatory agencies may regulate the manufacture of our products.

Federal, state, local and international regulations regarding the manufacture and sale of health care products and diagnostic devices may change. In addition, as we continue to sell in foreign markets, we may have to obtain additional governmental clearances in those markets.

To date, we have complied with the following federal, state, local and international regulatory requirements:

- United States Food and Drug Administration (“FDA”): In December 2010, August 2008, September 2005 and March 2003, the FDA conducted a facility inspection and verified our compliance with the 21 CFR 820 Regulation.
- United States Department of Agriculture: In October 2009, we received a United States Veterinary Biologics Establishment License from the United States Department of Agriculture.
- State of California Food and Drug Branch (“FDB”): In April 2001, the FDB granted our manufacturing facility “in compliance” status, based on the regulations for Good Manufacturing Practices for medical devices. In May 2001, the FDB granted licensing for our manufacturing facility in Union City, California. In December 2010, the FDB conducted a routine facility inspection and verified our compliance with Good Manufacturing Practices for medical devices.
- International Organization for Standardization (“ISO”): In May 2002, we received our ISO 9001 certification, expanding our compliance with international quality standards. In December 2003, we received ISO 13485 Quality System certification as required by the 2003 European In Vitro Device Directive. This certified our quality system specifically to medical devices. In April 2005, we received the Canadian Medical Device Conformity Assessment System stamp on our ISO 13485 certificate to signify compliance with Health Canada regulations. In October 2009, we received our recertification to the ISO 13485:2003 Quality System Standard for medical devices. In May 2010 and May 2011, we were recommended for continued certification to ISO 13485:2003 by our current ISO registrar.

We cannot assure you that we will successfully pass the latest FDA inspection or any re-inspection by the FDA or the State of California. In addition, we cannot assure you that we can comply with all current or future government manufacturing requirements and regulations. We cannot predict what impact, if any, such current or future regulatory changes would have on our business. We may not be able to obtain regulatory clearances for our products in the United States or in foreign markets, and the failure to obtain these regulatory clearances will materially adversely affect our business and results of operations. If we are unable to comply with the regulations, or if we do not pass routine inspections, our business and results of operations will be materially adversely affected. Although we believe that we will be able to comply with all applicable regulations of the FDA and of the State of California, including the Quality System Regulation, current regulations depend on administrative interpretations. Future interpretations made by the FDA, CMS or other regulatory bodies may adversely affect our business.

We have incurred and may continue to incur, in future periods, significant share-based compensation charges which may adversely affect our reported financial results.

In accordance with Accounting Standards Codification 718, "Compensation-Stock Compensation," issued by the Financial Accounting Standards Board, we measure all share-based payments to employees using a fair-value-based method and we record such expense in our results of operations. The fair value of restricted stock unit awards used in our expense recognition method is measured based on the number of shares granted and the closing market price of our common stock on the date of grant. Such value is recognized as an expense, net of an estimated forfeiture rate, over the corresponding requisite service period. Since fiscal 2007, we have granted restricted stock unit awards annually to employees based on the following time-based vesting schedule over a four-year period: five percent vesting after the first year; additional ten percent after the second year; additional 15 percent after the third year; and the remaining 70 percent after the fourth year of continuous employment. Since we began granting restricted stock units as part of our share-based compensation program in fiscal 2007, share-based compensation expense related to restricted stock units had a material impact on our earnings per share and on our consolidated financial statements and we expect that it will continue to adversely impact our reported results of operations, particularly in the fourth year of vesting for the restricted stock unit awarded to employees. As of December 31, 2011, our unrecognized compensation expense related to restricted stock unit awards granted to employees and directors to date totaled \$20.8 million, which is expected to be recognized over a weighted average service period of 2.29 years.

Table of Contents

We may inadvertently design or produce defective products, which may subject us to significant warranty liabilities or product liability claims. We may have insufficient product liability insurance to pay material uninsured claims.

Our business exposes us to potential warranty and product liability risks that are inherent in the design, testing, manufacturing and marketing of human and veterinary medical products. Although we have established procedures for quality control on both the raw materials that we receive from suppliers as well as the design and manufacturing of our products, these procedures may prove inadequate to detect a design or manufacturing defect. In addition, our Piccolo and VetScan chemistry analyzers may be unable to detect all errors that could result in the misdiagnosis of human or veterinary patients.

We may be subject to substantial claims for defective products under our warranty policy or product liability laws. In addition, our policy is to credit medical providers for any defective product that we produce, including those reagent discs that are rejected by our Piccolo and VetScan chemistry analyzers. Therefore, even if a mass defect within a lot or lots of reagent discs were detected by our Piccolo and VetScan chemistry analyzers, the replacement of such reagent discs free of charge would be costly and could materially harm our financial condition. Further, in the event that a product defect is not detected in our Piccolo chemistry analyzer, our relatively recent expansion into the human medical market greatly increases the risk that the amount of damages involved with just one product defect would be material to our operations. Our product liability insurance and cash may be insufficient to cover potential liabilities. In addition, in the future the coverage that we require may be unavailable on commercially reasonable terms, if at all. Even with our current insurance coverage, a mass product defect, product liability claim or recall could subject us to claims above the amount of our coverage and would materially adversely affect our business and our financial condition.

We may experience manufacturing problems related to our instruments, which could materially and adversely affect our revenues and business.

We manufacture our blood chemistry analyzers at our manufacturing facility in Union City, California. Should we experience problems related to the manufacture of our blood chemistry analyzer, we could fail to achieve anticipated revenue or we may incur an additional increase in our cost of revenue. These problems may include manufacturing defects and product failures, defects in raw materials acquired from our suppliers, delays in receipt of raw materials from our suppliers, increases in raw materials costs and labor disturbances. For example, we experienced a higher rate of blood chemistry analyzer failures in fiscal 2008. Although we began experiencing a decrease in the estimated product failure rates on our instruments since we began taking steps to resolve these manufacturing problems, there can be no assurance that our efforts to resolve these manufacturing difficulties will continue to prove to be successful or that similar problems will not arise in the future. If we are unable to prevent similar problems from occurring in the future, we may not be able to manufacture sufficient quantities to meet anticipated demand and, therefore, will not be able to effectively market and sell our blood chemistry analyzers or other instruments that we market and sell; accordingly, our revenue and business would be materially adversely affected.

Fluctuations in foreign exchange rates and the possible lack of financial stability in foreign countries could prevent overseas sales growth.

For our international sales denominated in U.S. dollars, an increase in the value of the U.S. dollar relative to foreign currencies could make our products less competitive in international markets. For our sales denominated in foreign currencies, we are subject to fluctuations in exchange rates between the U.S. dollar and the particular foreign currency. Our operating results could also be adversely affected by the seasonality of international sales and the economic conditions of our overseas markets.

We are subject to increasingly complex requirements from legislation requiring companies to evaluate internal control over financial reporting.

Rules adopted by the Securities and Exchange Commission pursuant to Section 404 of the Sarbanes-Oxley Act of 2002 require an assessment of internal control over financial reporting by our management and an attestation of the effectiveness of our internal control over financial reporting by an independent registered public accounting firm. We have an ongoing program to perform the assessment, testing and evaluation to comply with these requirements and we expect to continue to incur significant expenses for Section 404 compliance on an ongoing basis.

Table of Contents

Our management assessed the effectiveness of our internal control over financial reporting as of our fiscal years ended March 31, 2011 and 2010. Although we received an unqualified opinion on our consolidated financial statements for the fiscal years ended March 31, 2011 and 2010, and on the effectiveness of our internal control over financial reporting as of March 31, 2011 and 2010, we cannot predict the outcome of our testing in future periods. In the event that our internal control over financial reporting is not effective as defined under Section 404, or any failure to implement required new or improved controls, or difficulties encountered in implementation could harm operating results or prevent us from accurately reporting financial results or cause a failure to meet our reporting obligations in the future. If management cannot assess internal control over financial reporting is effective, or our independent registered public accounting firm is unable to provide an unqualified attestation report on such assessment, investor confidence and our share value may be negatively impacted.

We must comply with strict and potentially costly environmental regulations or we could pay significant fines.

We are subject to stringent federal, state and local laws, rules, regulations and policies that govern the use, generation, manufacture, storage, air emission, effluent discharge, handling and disposal of certain materials and wastes. In particular, we are subject to laws, rules and regulations governing the handling and disposal of biohazardous materials used in the development and testing of our products. Our costs to comply with applicable environmental regulations consist primarily of handling and disposing of human and veterinary blood samples for testing (whole blood, plasma, serum). Although we believe that we have complied with applicable laws and regulations in all material respects and have not been required to take any action to correct any noncompliance, we may have to incur significant costs to comply with environmental regulations if our manufacturing to commercial levels continues to increase. In addition, if a government agency determines that we have not complied with these laws, rules and regulations, we may have to pay significant fines and/or take remedial action that would be expensive and we do not carry environmental-related insurance coverage.

Our operating results could be materially affected by unanticipated changes in our tax provisions or exposure to additional income tax liabilities.

Our determination of our tax liability is subject to review by applicable tax authorities. Any adverse outcome of such a review could have an adverse effect on our operating results and financial condition. In addition, the determination of our provision for income taxes and other tax liabilities requires significant judgment including our determination of whether a valuation allowance against deferred tax assets is required. Although we believe our estimates and judgments are reasonable, the ultimate tax outcome may differ from the amounts recorded in our consolidated financial statements and may materially affect our financial results in the period or periods for which such determination is made.

Our stock price is highly volatile and investing in our stock involves a high degree of risk, which could result in substantial losses for investors.

The market price of our common stock, like the securities of many other medical products companies, fluctuates over a wide range, and will continue to be highly volatile in the future. During the quarter ended December 31, 2011, the closing sale prices of our common stock on the NASDAQ Global Market ranged from \$22.15 to \$28.54 per share and the closing sale price on December 30, 2011, the last day of trading for our quarter ended December 31, 2011 was \$27.67 per share. During the last eight fiscal quarters ended December 31, 2011, our stock price closed at a high of \$31.44 per share on May 19, 2011 and a low of \$17.74 per share on July 19, 2010. Many factors may affect the market price of our common stock, including:

- fluctuation in our operating results;

Edgar Filing: ABAXIS INC - Form 10-Q

- announcements of technological innovations or new commercial products by us or our competitors;
- changes in governmental regulation in the United States and internationally;
- prospects and proposals for health care reform;
- governmental or third-party payors' controls on prices that our customers may pay for our products;
- developments or disputes concerning our patents or our other proprietary rights;
- product liability claims and public concern as to the safety of our devices or similar devices developed by our competitors; and
- general market conditions.

Because our stock price is so volatile, investing in our common stock is highly risky. A potential investor must be able to withstand the loss of his entire investment in our common stock.

Table of Contents

Our shareholders rights plan and our ability to issue preferred stock may delay or prevent a change of control of Abaxis.

Our shareholder rights plan, adopted by our board of directors on April 22, 2003, may make it more difficult for a third party to acquire, or discourage a third party from attempting to acquire control of, Abaxis. The shareholder rights plan could limit the price that investors might be willing to pay in the future for shares of our common stock.

In addition, our board of directors has the authority to issue up to 5,000,000 shares of preferred stock and to determine the price, rights, preferences, privileges and restrictions, including voting rights, of those shares without any further vote or action by the shareholders, except to the extent required by NASDAQ rules. The issuance of preferred stock, while providing flexibility in connection with possible financings or acquisitions or other corporate purposes, could have the effect of making it more difficult for a third party to acquire a majority of our outstanding voting stock and, consequently, negatively affect our stock price.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

The following table presents information with respect to purchases of common stock of Abaxis made during the three months ended December 31, 2011 by Abaxis, as defined in Exchange Act Rule 10b-18(a)(3):

	Total Number of Shares Purchased	Average Price Paid Per Share Including Commissions	Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs	Maximum Number (or approximate dollar amount) of Shares that May Yet be Purchased Under the Plans or Programs
Month #1 (October 1, 2011 to October 31, 2011)	-	\$ -	-	\$ 12,672,000
Month #2 (November 1, 2011 to November 30, 2011)	-	\$ -	-	\$ 12,672,000
Month #3 (December 1, 2011 to December 31, 2011)	-	\$ -	-	\$ 12,672,000
Total	-	\$ -	-	

On August 5, 2011, the Board of Directors authorized the repurchase of up to an aggregate of \$40.0 million of our common stock. The share repurchase program was announced on August 8, 2011. As of December 31, 2011, \$12.7 million of shares repurchases may yet be purchased under such authorization. In January 2012, the Board of Directors approved a \$15.0 million increase to its existing share repurchase program, to a total of \$55.0 million. The repurchases are made from time to time on the open market at prevailing market prices or in negotiated transactions off the market.

Pursuant to the Master Agreement with NISTAC and KSURF, two entities affiliated with Kansas State University, as further described in Note 12 of the Notes to Condensed Consolidated Financial Statements in Part I, Item 1, we were obligated to issue to NISTAC a warrant to purchase 20,000 shares of our common stock on the date we first received samples from a paying customer, as described in our Master Technical Testing Services Agreement with the Kansas State University and K-State Diagnostic and Analytical Services Inc. We issued such warrant on October 3, 2011. The exercise price of the warrant is \$3.00 per share and the warrant vests at a rate of 20% annually from its

issuance date and has a term of five years. The issuance is exempt from registration requirements pursuant to Section 4(2) of the Securities Act of 1933, as amended.

Item 3. Defaults Upon Senior Securities

Not applicable.

Item 4. Removed and Reserved

Item 5. Other Information

Not applicable.

Table of Contents

Item 6. Exhibits

Exhibit No. Description of Document

3.1	Restated Articles of Incorporation (Filed with the Securities and Exchange Commission as an exhibit with our Annual Report on Form 10-K for the fiscal year ended March 31, 1993 and incorporated herein by reference.)
3.2	Certificate of Amendment of Amended and Restated Articles of Incorporation (Filed with the Securities and Exchange Commission as an exhibit with our Quarterly Report on Form 10-Q for the quarterly period ended December 31, 1996 and incorporated herein by reference.)
3.3	By-laws (Filed with the Securities and Exchange Commission in our Registration Statement No. 33-44326 on December 11, 1991 and incorporated herein by reference.)
3.4	Amendment to the By-laws (Filed with the Securities and Exchange Commission as an exhibit with our Current Report on Form 8-K on July 30, 2007 and incorporated herein by reference.)
4.1	Registration Rights Agreement, dated as of March 29, 2002 (Filed with the Securities and Exchange Commission as an exhibit with our Current Report on Form 8-K on May 13, 2002 and incorporated herein by reference.)
4.2	Reference is made to Exhibit 3.1, Exhibit 3.2, Exhibit 3.3 and Exhibit 3.4.
<u>31.1</u>	Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
<u>31.2</u>	Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
<u>32.1#</u>	Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
<u>32.2#</u>	Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101#	The following materials from Abaxis' Quarterly Report on Form 10-Q for the quarter ended December 31, 2011, formatted in XBRL (Extensible Business Reporting Language): (i) unaudited Condensed Consolidated Statements of Income for the three and nine months ended December 31, 2011 and 2010, (ii) unaudited Condensed Consolidated Balance Sheets as of December 31, 2011 and March 31, 2011, (iii) unaudited Condensed Consolidated Statements of Cash Flows for the nine months ended December 31, 2011 and 2010, and (iv) Notes to Condensed Consolidated Financial Statements.

#These exhibits are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of Abaxis, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report on Form 10-Q and irrespective of any general incorporation language contained in any such filing.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ABAXIS, INC.
(Registrant)

Date: February 9, 2012

By: /s/ Clinton H. Severson

Clinton H. Severson
President, Chief Executive Officer and
Director
(Principal Executive Officer)

Date: February 9, 2012

By: /s/ Alberto R. Santa Ines

Alberto R. Santa Ines
Chief Financial Officer and Vice
President of Finance
(Principal Financial and Accounting
Officer)